%PDF-1.3 % 2 0 obj <> endobj 3 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 10 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 19 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 22 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 13 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 14 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 4 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 20 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 18 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 23 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 16 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 9 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 12 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 24 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 6 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 11 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 15 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 25 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 17 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 7 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0P02S04S  @$P5 )1 endstream endobj 5 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 1 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 8 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5T0q-Br44C@B 9 s (P endstream endobj 21 0 obj <>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream xs w3T04PI2P0T5TR Ɩf !\!Y\ !p)P endstream endobj 26 0 obj <>stream 3B2 Total Publishing System 7.51o/W 2014-01-14T06:12:39-08:00 2011-06-11T16:07:22+05:30 application/pdf untitled Acrobat Distiller 8.1.0 (Windows) uuid:8d5c00de-a90b-4658-a9b3-07131fb53654 uuid:6c49e328-a846-4129-aef1-d71b98283eaf endstream endobj 27 0 obj <>stream x+| endstream endobj 28 0 obj <>stream xS**T0T0Bih] 9D. qaj endstream endobj 29 0 obj <>stream x+| endstream endobj 30 0 obj <>stream xS**T0T0Bih] D. pa endstream endobj 31 0 obj <>stream x+| endstream endobj 32 0 obj <>stream xS**T0T0BiU!D. _e1 endstream endobj 33 0 obj <>stream x+| endstream endobj 34 0 obj <>stream xS**T0T0Bih]D. r^j endstream endobj 35 0 obj <>stream x+| endstream endobj 36 0 obj <>stream xS**T0T0BiU)D* 9V endstream endobj 37 0 obj <>stream x+| endstream endobj 38 0 obj <>stream xS**T0T0BiUD* 8 endstream endobj 39 0 obj <>stream x+| endstream endobj 40 0 obj <>stream xS**T0T0Bid]1D. pa endstream endobj 41 0 obj <>stream x+| endstream endobj 42 0 obj <>stream xS**T0T0BiUD* : endstream endobj 43 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 54 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 55 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 45 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 62.022 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(et)-278.6(al.)-277.8(2004,)-272.9(Sanbonmatsu-Gamez)-286.1(et)-278.6(al.)-277.8(2005\).)-273.3(Investigation)-284.8(of)]TJ 0 -1.2203 TD [(TOSV-specic)-293.7(immunoglobulins)-293.7(is)-289.4(also)-291.7(important)-294.3(for)-288.5(identi-)]TJ 0 -1.2266 TD [(fying)-288.1(virus)-292.2(exposure)-294(in)-291.4(healthy)-286.5(subjects)-297.5(from)-286(endemic)-291.1(coun-)]TJ 0 -1.2203 TD [(tries)-530.7(or)-528.3(in)-525.4(regions)-528.2(where)-530.3(the)-528.6(sandy)-526.8(vectors)-530(are)-524.9(present)]TJ T* [(\(Dionisio)-370.5(et)-367.1(al.)-360(2003\).)-368.2(The)-360.4(early)-368.5(phase)-365.9(of)-363.6(the)-370.5(SFV)-366.1(disease)-362.6(is)]TJ 0 -1.2266 TD [(characterized)-230(by)-230.1(a)-220.8(slow)-230.5(increase)-228.8(in)-228.2(specic)-229(IgMs,)-224.5(followed)-232.6(by)]TJ 0 -1.2203 TD [(IgG)-416.3(several)-416.6(days)-419.2(afterward)-416.9(in)-417.9(the)-421.1(serum)-418.1(\(Echevarria)-421.7(et)-417.7(al.)]TJ T* [(2003\).)-286(IgM)-289.9(can)-286.7(still)-290.6(be)-288.8(detected)-290.4(at)-284.5(least)-289.3(1)-290.4(year)-282.7(after)-291.9(the)-288.3(expo-)]TJ 0 -1.2266 TD [(sure,)-467.8(whereas)-467.9(IgG)-460.5(levels)-470.5(slowly)-466.1(increase,)-465.7(reaching)-469.4(a)-461.1(peak)]TJ 0 -1.2203 TD [(in)-588.6(the)-585.5(convalescent)-588.9(phase)-593.5(and)-581.3(persists)-591.6(for)-585.6(several)-587.3(years)]TJ T* [(\()-82.7(Magurano)-231.8(and)-227.2(Nicoletti)-234.8(1999\).)-222.7(Various)-233.3(methods)-229.7(can)-229.8(be)-225.6(used)]TJ T* [(for)-433.9(the)-440(detection)-436.3(of)-433.2(TOSV)-437.3(IgM)-435.3(and/or)-429.7(IgG)-435.2(antibodies,)-435.7(in-)]TJ 0 -1.2266 TD [(cluding)-473.8(hemagglutination)-480.1(inhibition,)-477.5(indirect)-475.4(immunouo-)]TJ 0 -1.2203 TD [(rescence)-579(test)-571.2(\(IIFT\),)-578.2(enzyme-linked)-573(immunosorbent)-575.6(assay)]TJ T* [(\(ELISA\),)-188.9(immunoblot)-194.4(\(IB\),)-186(and)-189.3(virus)-184.7(neutralization)-198.6(test)-185.5(\(VNT\))]TJ 0 -1.2266 TD [(\(Clarke)-318.5(and)-315.7(Cassals)-316.5(1958,)-317.1(Eitrem)-315(et)-316.5(al.)-315.8(1991b,)-315.2(Schwarz)-312.3(et)-316.5(al.)]TJ 0 -1.2203 TD [(1995,)-310.8(1996,)-317.1(Magurano)-314(and)-315.7(Nicoletti)-317(1999\).)-311.3(Some)-314.9(of)-313.1(these)-321.1(as-)]TJ T* [(says)-449.2(are)-455.4(commercially)-447.9(available)-456.8(and)-448.5(have)-452.5(been)-450.2(developed)]TJ 0 -1.2266 TD [(with)-211.3(partially)-206.3(puried)-208.9(antigens,)-208.5(infected)-212.3(cells,)-206.5(or)-205.8(recombinant)]TJ 0 -1.2203 TD [(viral)-596(proteins)-601.5(\(Eitrem)-600(et)-601(al.)-594(1991b,)-599.7(Schwarz)-596.9(et)-594.7(al.)-600.3(1995,)]TJ T* [(Schwartz)-281.2(et)-284.9(al.)-277.8(1998,)-279.2(Ciufolini)-287.8(et)-278.6(al.)-277.8(1999\).)]TJ 1.1128 -1.2203 TD [(Exposure)-467.8(to)-464.8(a)-467.4(particular)-465.2(SFV)-467.3(serotype)-466.1(does)-468.6(not)-468.2(protect)]TJ -1.1128 -1.2266 TD [(from)-342.9(infection)-345.5(with)-344.1(another)-345.2(serotype,)-348.9(and)-341(cross-reactions)-351.8(in)]TJ 0 -1.2203 TD [(serological)-400.6(tests)-395.5(can)-394.2(be)-396.3(frequently)-397.9(observed)-398.4(\(Dionisio)-395.8(et)-398.7(al.)]TJ T* [(2003\).)-500.9(Pre-existing)-501.7(antibodies)-502.4(against)-499(SFV)-498.9(serotypes)-499(other)]TJ 0 -1.2266 TD [(than)-228.1(TOSV)-222.3(\(SFSV)-226(or)-224.8(SFNV\))-227.5(may)-222.8(also)-222.1(interfere)-230.3(with)-224(the)-231.4(TOSV)]TJ 0 -1.2203 TD [(serology)-196.9(results)-198.3(and)-189.3(can)-198.2(be)-187.7(interpreted)-203(as)-190.5(false-positive)-202.2(due)-193.9(to)]TJ T* [(the)-199.8(cross-reactivity.)-198.4(This)-200.9(is)-194.5(more)-196.9(likely)-196.4(to)-192.9(occur)-199.4(when)-198(partially)]TJ 0 -1.2266 TD [(puried)-310(virus)-311.1(extracts)-313.6(or)-313.3(SFV-infected)-313.3(cells)-311.1(are)-309.9(employed)-315.9(as)]TJ 0 -1.2203 TD [(the)-319.9(source)-327.8(of)-319.4(antigens)-319.4(in)-323.1(the)-319.9(assay)-322.2(used)-321.7(for)-320.1(the)-326.2(diagnosis)-320(or)]TJ T* [(surveillance)-471.9(\(Schwarz)-464.5(et)-468.3(al.)-467.5(1995,)-462.5(Magurano)-465.7(and)-467.5(Nicoletti)]TJ 0 -1.2266 TD [(1999\).)-241.7(During)-242.4(human)-245.5(immune)-243.6(response)-244.6(to)-243.5(TOSV)-247.6(infection,)-247.3(N)]TJ 0 -1.2203 TD [(protein)-277.7(has)-282.4(been)-273.2(identied)-285.3(as)-272.7(the)-282(immunodominant)-279.1(antigen,)]TJ T* [(which)-365.3(has)-364.6(later)-358.2(been)-368(used)-359.7(for)-364.3(developing)-364(diagnostic)-369(assays)]TJ T* [(with)-388.4(recombinant)-394.3(proteins)-392.8(\(Ciufolini)-389.5(et)-386.1(al.)-391.7(1999,)-386.7(Cusi)-385.7(et)-392.4(al.)]TJ 0 -1.2266 TD [(2001\).)-444(The)-448.9(recombinant)-451.2(N)-448.9(protein-based)-450.7(assays)-443.7(have)-446.1(been)]TJ 0 -1.2203 TD [(previously)-234.6(evaluated)-235.5(and)-233.5(have)-231.2(performed)-234(well,)-232.8(especially)-237.6(for)]TJ T* [(acute)-240.8(TOSV)-241.3(infections)-245.7(\(Valassina)-242.5(et)-240.6(al.)-239.9(1998,)-234.9(Soldateschi)-249.1(et)-240.6(al.)]TJ 0 -1.2266 TD [(1999\).)-342.9(Nevertheless,)-349.1(cross-reactivity)-353.5(in)-342(phlebovirus)-345.5(serology)]TJ 0 -1.2203 TD [(affects)-387.1(the)-383.1(assays)-386.8(that)-383.2(employ)-388.9(TOSV)-380.4(N)-385.7(protein)-385.2(as)-386.5(well,)-384.6(es-)]TJ T* [(pecially)-223.7(in)-221.9(regions)-224.7(where)-226.8(different)-226.8(phleboviruses)-226.6(co-circulate,)]TJ 0 -1.2266 TD [(due)-339.4(to)-338.4(the)-338.9(presence)-347.2(of)-338.4(highly)-338.8(conserved)-346.1(regions)-338.5(in)-335.7(the)-345.2(viral)]TJ 0 -1.2203 TD [(nucleocapsid)-321.7(\()-82.7(Magurano)-320.3(and)-315.7(Nicoletti)-323.3(1999,)-310.8(Di)-321.1(Bonito)-313.1(et)-322.8(al.)]TJ T* [(2002\).)-323.9(To)-321.9(discriminate)-331.9(among)-323.8(related)-323.2(phleboviruses,)-330.6(it)-326.5(is)-321(re-)]TJ T* [(commended)-562.8(to)-559.7(complement)-562.1(recombinant)-565(N-protein-based)]TJ 0 -1.2266 TD [(serodiagnosis)-343.6(with)-331.5(VNT)-340.9(\(Calisher)-335(et)-335.5(al.)-341.1(1999,)-329.8(Dionisio)-338.4(et)-341.8(al.)]TJ 0 -1.2203 TD [(2003\).)-317.6(However,)-318.4(phlebovirus)-326.5(neutralization)-318.8(has)-320.4(been)-317.4(shown)]TJ T* [(to)-439.5(be)-434.3(mediated)-436.8(only)-437.7(partially)-440.2(by)-432.5(antibodies)-439.2(to)-439.5(the)-440(nucleo-)]TJ 0 -1.2267 TD [(capsid,)-434.6(and)-435.9(immunity)-435.5(to)-433.2(viral)-438(envelope)-435.1(glycoproteins)-445.2(also)]TJ 0 -1.2203 TD [(plays)-332.6(a)-334.6(role)-335.7(\(Cusi)-329.3(et)-335.5(al.)-334.8(2001,)-329.8(Di)-333.7(Bonito)-332.1(et)-335.5(al.)-334.8(2002\).)-330.2(The)-335.1(im-)]TJ T* [(mune)-198.2(response)-194(to)-192.9(viral)-197.7(glycoproteins)-198.6(has)-193.9(been)-191(shown)-195.9(to)-192.9(differ)]TJ 0 -1.2266 TD [(among)-380.7(patients,)-385.9(whereas)-385.7(all)-386(exposed)-383.4(persons)-383.8(develop)-384.3(anti-)]TJ 0 -1.2203 TD [(bodies)-356.4(against)-359.9(linear)-358.3(epitopes)-364.7(of)-357.3(N)-360.4(protein)-359.9(\(Di)-359.5(Bonito)-357.4(et)-360.8(al.)]TJ T* [(2002\).)-380.8(Interpretation)-385.4(of)-376.3(serological)-381.7(assay)-379.1(results)-381.6(in)-373.6(endemic)]TJ 0 -1.2266 TD [(regions)-363.8(may)-361.9(be)-364.7(more)-361.3(difcult,)-365.3(due)-364.7(to)-363.6(frequent)-364.7(recent)-364(infec-)]TJ 0 -1.2203 TD [(tions)-258.1(and/or)-259(reinfections)-265.2(that)-256.8(boost)-258.3(immunity)-258.4(\(Calisher)-259.1(et)-259.6(al.)]TJ T* [(1999,)-279.2(Dionisio)-287.8(et)-278.6(al.)-277.8(2003\).)]TJ 1.1128 -1.2203 TD [(The)-278.2(aim)-285.1(of)-281.5(this)-280.6(study)-282.4(was)-280.7(to)-281.4(evaluate)-283.1(the)-282(performances)-285.1(of)]TJ -1.1128 -1.2266 TD [(all)-221.6(commercially)-226.6(available)-222.8(serological)-223.6(assays)-222.4(utilizing)-225.6(various)]TJ 0 -1.2203 TD [(antigen)-545.7(sources)-550.4(for)-547.7(detecting)-545.5(anti-TOSV)-552.2(antibodies,)-543.2(com-)]TJ T* [(pared)-396.5(to)-395.3(virus)-399.7(neutralization)-400.9(in)-398.9(samples)-396.5(from)-393.5(a)-397.9(TOSV)-393(and)]TJ 0 -1.2267 TD [(SFV)-283.9(endemic)-278.5(region)-286.6(\(Ergu)]TJ 11.1283 .0126 TD ()Tj .4679 -.0126 TD [(nay)-285.5(et)-278.6(al.)-277.8(2010\).)]TJ /F3 1 Tf 16.4016 74.5598 TD [(Materials)-339(and)-331.9(Methods)]TJ /F10 1 Tf 0 -1.8336 TD [(Samples)-338.1(and)-335.7(commercial)-334.1(assays)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Serum)-282.5(samples)-289(reactive)-282.2(for)-288.5(SFV)-283.9(IgG)-277.2(by)-287(a)-277.7(commercial)-288.2(IIFT)]TJ -1.1128 -1.2203 TD [(\(SFV)-423.5(IgG)-422.6(mosaic)-421.3(I;)-422.3(Euroimmun\))-422.7(performed)-423.7(during)-421.1(a)-416.8(sero-)]TJ 0 -1.2266 TD [(surveillance)-522.5(study)-510.1(in)-519.1(Central)-513.5(Anatolia,)-516.5(Turkey,)-509.9(were)-514.3(em-)]TJ 0 -1.2203 TD [(ployed)-590.4(in)-582.3(the)-585.5(study)-586(\(Ergu)]TJ 12.0704 .0126 TD ()Tj .4679 -.0126 TD [(nay)-582.7(et)-588.4(al.)-581.3(2010\).)-583.1(The)-581.7(samples)]TJ -12.5383 -1.2203 TD [(originated)-191.9(from)-191.2(healthy)-191.7(blood)-193.5(donors)-191(and)-182.9(were)-191.8(obtained)-194(after)]TJ 0 -1.2266 TD [(informed)-289.5(consent.)-285.3(The)-278.2(IIFT)-283.5(allows)-277.9(simultaneous)-287.9(detection)-284.6(of)]TJ 0 -1.2203 TD [(antibodies)-338(against)-340.9(four)-334.1(viral)-336.8(serotypes)-340.9(\(SFSV,)-336.4(SFNV,)-331.1(TOSV,)]TJ T* [(and)-423.2(SFCV\))-423.7(and)-416.9(was)-419.8(performed)-423.7(as)-424.5(indicated)-420.3(by)-419.8(the)-421.1(manu-)]TJ T* [(facturer.)-346.7(A)-342.8(total)-341.9(of)-344.7(120)-340(samples)-345.9(were)-343.6(retested)-340.8(via)-345.2(this)-343.8(assay)]TJ 0 -1.2266 TD [(before)-318(inclusion)-319.3(in)-310.4(the)-313.6(study)-314.1(and)-315.7(reactive)-313.9(sera)-311.2(were)-312(divided)]TJ 0 -1.2203 TD [(into)-408.5(six)-405.3(panels)-407.3(according)-407.9(to)-407.9(the)-408.4(IIFT)-403.7(IgG)-403.6(reactivity)-410.9(against)]TJ T* [(different)-290(viral)-279.9(serotypes:)-280.6(Panel)-285.9(1:)-274.3(SFSV)-282.4(\(n:18\);)-281.1(Panel)-285.9(2:)-280.6(SFNV)]TJ 0 -1.2266 TD [(\(n:11\);)-445.5(Panel)-437.6(3:)-438.7(TOSV)-443.6(\(n:46\);)-439.1(Panel)-444(4:)-438.7(SFCV)-442.2(\(n:7\);)-439.6(Panel)-437.6(5:)]TJ 0 -1.2203 TD (SFSV)Tj /F11 1 Tf 2.3142 0 TD ()Tj /F5 1 Tf .7714 0 TD [(SFCV)-499.1(\(n:13\);)-496.1(and)-492.8(Panel)-500.9(6:)-489.3(SFNV)]TJ /F11 1 Tf 15.1497 0 TD ()Tj /F5 1 Tf .7714 0 TD [(TOSV)-494.2(\(n:25\).)-496.1(All)]TJ -19.0067 -1.2203 TD [(samples)-232.1(were)-229.8(further)-234.6(evaluated)-235.5(for)-225.2(SFV)-233.3(IgM)-226.6(by)-230.1(a)-227.1(commercial)]TJ 0 -1.2266 TD [(IIFT)-258.2(\(SFV)-252.8(IgM)-251.9(Mosaic)-251.8(I;)-251.6(Euroimmun\),)-254.9(for)-256.9(TOSV)-253.9(IgM/IgG)-247.6(by)]TJ 0 -1.2203 TD [(a)-353.6(commercial)-351.4(ELISA)-349.4(\(TOSV)-349.3(IgG)-346.7(and)-353.7(IgM;)-343.4(Diesse\))-355.6(and)-347.3(by)-350.3(a)]TJ T* [(commercial)-395.7(IB)-390.8(assay)-385.4(for)-396(TOSV)-386.7(IgG)-391(\(recomLine)-389.9(Bunyavirus)]TJ T* [(IgG/IgM;)-566.6(Mikrogen\))-562.2(according)-566(to)-566(the)-560.2(manufacturers)-570.2(in-)]TJ 0 -1.2266 TD [(structions.)-302.1(In)-296.4(addition)-297.4(to)-300.4(TOSV,)-294.8(antibodies)-300(to)-294.1(certain)-297.6(Hanta-)]TJ 0 -1.2203 TD [(virus)-254.2(serotypes)-252.4(\(Hantaan,)-249.4(Puumala,)-253.7(Dobrava,)-245.9(and)-246.2(Seoul\))-253.1(can)]TJ T* [(also)-329.6(be)-333.1(simultaneously)-327.5(detected)-334.7(via)-326.3(the)-332.5(IB.)-324.2(In)-334.3(the)-326.2(IIFT,)-330.7(anti-)]TJ 0 -1.2266 TD [(body)-235.9(levels)-236.5(were)-236.1(determined)-239(starting)-241.4(at)-233.9(the)-237.7(serum)-234.8(dilution)-236.6(of)]TJ 0 -1.2203 TD [(1:100.)-655.1(The)-657.5(positive)-658.6(results)-653.5(were)-659.7(evaluated)-659.2(as)-652.1(equivocal)]TJ T* [(\(1/100\),)-194.6(positive)-190.7(\(1/320\),)-188.3(or)-186.8(strong)-196.4(positive)-190.7(\(1/1000)-190.7(or)-186.8(higher\))]TJ 0 -1.2266 TD [(according)-509.1(to)-509.1(visual)-509.5(intensity)-507.3(of)-509.1(uorescence)-510.3(compared)-503.6(to)]TJ 0 -1.2203 TD [(control)-208.9(sera.)-200.4(In)-201.5(the)-206.1(ELISA,)-200.6(qualitative)-206.7(evaluation)-204.4(of)-199.3(the)-206.1(results)]TJ T* [(was)-223.8(performed)-227.7(by)-223.8(comparing)-227.5(the)-225.1(average)-226(optic)-222.4(density)-224.7(of)-224.5(the)]TJ 0 -1.2266 TD [(sample)-420.5(with)-420(the)-421.1(cutoff)-422.1(control.)-426.8(When)-416.7(the)-421.1(sample)-420.5(to)-420.6(cutoff)]TJ 0 -1.2203 TD [(ratio)-386.4(was)]TJ /F12 1 Tf 4.5462 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1.2,)-377.9(the)-383.1(sample)-388.9(was)-381.8(interpreted)-386.4(as)-380.2(positive)-386.7(and)]TJ -5.3176 -1.2203 TD [(borderline)-262.1(if)-256.9(the)-256.7(ratio)-253.6(was)-255.4(between)-256.2(1.2)-254.9(and)-252.5(0.8.)-257.8(The)-252.9(IB)-258(results)]TJ T* [(are)-303.6(interpreted)-304.2(according)-306.7(to)-300.4(the)-300.9(visual)-307.2(intensity)-304.9(of)-300.4(the)-300.9(cutoff)]TJ 0 -1.2266 TD [(control)-190(where)-182.6(intensities)-185.1(equal)-179.4(to)-186.6(the)-180.8(cutoff)-188.2(as)-177.9(positive)-184.3(\()]TJ /F11 1 Tf 23.7172 0 TD ()Tj /F5 1 Tf .7714 0 TD [(\))-183.8(and)]TJ -24.4886 -1.2203 TD [(stronger)-317.2(than)-316.6(the)-319.9(cutoff)-314.6(as)-310.6(strong)-316.6(positive)-317.1(\()]TJ /F11 1 Tf 19.209 0 TD ()Tj /F5 1 Tf 1.5428 0 TD (,)Tj /F11 1 Tf .5627 0 TD ()Tj /F5 1 Tf 2.3142 0 TD [(\))-310.3(a)0(s)-317(in-)]TJ -23.6287 -1.2203 TD [(dicated)-375.4(by)-375.6(the)-370.5(manufacturer.)-380.2(The)-373(general)-371.8(features)-376.7(and)-372.6(per-)]TJ 0 -1.2266 TD [(formance)-825.6(characteristics)-834.2(of)-818.9(the)-825.7(commercial)-825.6(assays)-823(are)]TJ 0 -1.2203 TD [(provided)-286.9(in)-278.8(Table)-282.2(1.)]TJ /F10 1 Tf 0 -2.447 TD [(Virus)-336(neutralization)-340.4(test)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(VNT)-284(for)-275.8(SFVs)-278.9(were)-280.3(performed)-284.6(in)-278.8(96-well)-280(microtiter)-287.1(plates)]TJ -1.1128 -1.2203 TD [(with)-413.7(Vero)-417.2(cells)-412.2(\(ATCC)-409.9(CCL81\))-413.8(and)-410.6(was)-407.1(adapted)-411.4(from)-412.5(the)]TJ T* [(VNT)-435.8(used)-435.5(for)-433.9(Rift)-432.3(Valley)-431(fever)-438(virus)-431.3(described)-432.4(previously)]TJ T* [(\(Davies)-348.3(et)-348.1(al.)-341.1(1988\).)-349.2(Serial)-347.1(serum)-342.3(dilutions)-351.7(of)-344.7(1/10)-343(to)-344.7(1/320)]TJ 0 -1.2266 TD [(and)-492.8(virus)-488.2(suspensions)-488.8(of)-490.1(10)]TJ 6.7246 0 0 5.9768 429.7888 220.1952 Tm (8)Tj 8.9663 0 0 8.9663 437.4991 216.17 Tm (TCID)Tj 6.7246 0 0 5.9768 459.1558 214.696 Tm (50)Tj 8.9663 0 0 8.9663 470.2676 216.17 Tm [(were)-489(prepared)-487(with)]TJ -17.5334 -1.2203 TD [(standard)-270.1(strains)-263.1(\(SFSV)-270.2(Oct-85)-267.9(Sabin,)-265.2(SFNV)-264.9(Oct-85)-261.5(Sabin)-268.6(and)]TJ T* [(TOSV)-342.5(ISS.Phl.3\).)-338.6(The)-341.4(viruses)-337.6(were)-343.6(then)-335.9(diluted)-343.6(to)-338.4(contain)-341.1(a)]TJ 0 -1.2266 TD [(nal)-243.4(concentration)-246.5(of)-243.5(100)-238.8(TCID)]TJ 6.7246 0 0 5.9768 435.5148 181.8141 Tm (50)Tj 8.9663 0 0 8.9663 444.4156 183.2881 Tm [(per)-242.2(50)]TJ /F13 1 Tf 2.8516 0 TD (m)Tj /F5 1 Tf .5564 0 TD [(L.)-239.9(The)-240.2(diluted)-242.4(virus)]TJ -18.0582 -1.2203 TD [(and)-309.4(serum)-304.3(dilutions)-307.4(were)-305.6(distributed)-312.5(into)-301(all)-303.8(wells)-307.1(excepted)]TJ T* [(for)-206.3(the)-199.8(controls.)-200.5(After)-198.9(an)-198.9(hour)-204.2(of)-199.2(incubation)-205(at)-196(37)]TJ /F14 1 Tf 20.9288 0 TD (8)Tj /F5 1 Tf .3857 0 TD [(C,)-199.1(Vero)-202.2(cells)]TJ -21.3145 -1.2266 TD (\()Tj /F14 1 Tf .3288 0 TD (*)Tj /F5 1 Tf .999 0 TD (2.10)Tj 6.7246 0 0 5.9768 340.6109 154.4315 Tm (5)Tj 8.9663 0 0 8.9663 347.8109 150.4062 Tm [(in)-430.6(number)-424.6(per)-431.9(well\))-426.4(in)-430.6(10%)-424.3(fetal)-427.5(calf)-426.4(serum)-430.8(were)]TJ -3.8759 -1.2203 TD [(added)-204.4(to)-205.6(the)-199.8(serumvirus)-204(complex.)-205.5(Cells)-204.5(were)-204.5(evaluated)-203.9(after)]TJ T* [(72)-346.8(and)-347.3(96)-163.4(h)-351.2(o)0(f)-344.7(incubation)-350.4(at)-347.7(37)]TJ /F14 1 Tf 13.8345 0 TD (8)Tj /F5 1 Tf .3857 0 TD [(C,)-344.5(and)-347.3(reactivity)-347.7(was)-343.9(deter-)]TJ -14.2202 -1.2267 TD [(mined)-431(by)-432.5(the)-427.4(lack)-430.4(of)-433.2(cytopathogenic)-436(effect)-430.4(above)-431(a)-429.5(serum)]TJ 0 -1.2203 TD [(dilution)-287.2(of)-281.5(1/20)-279.8(at)-278.2(the)-282(96th)-281.1(hour.)]TJ /F10 1 Tf 0 -2.4406 TD [(Statistical)-342.4(analysis)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Agreement)-210(among)-210(commercial)-206(assays)-203.4(by)-204.8(the)-212.4(Kappa,)-203.5(Fleiss)]TJ -1.1128 -1.2267 TD [(Kappa)-282.8(coefcients)-278.9(\(Landis)-279.8(and)-277.8(Koch)-280.1(1977,)-279.2(Ilstrup)-276.4(1990\),)-279.6(and)]TJ /F3 1 Tf -27.9978 77.2217 TD (782)Tj 46.1193 0 TD (ERGU)Tj 2.3648 .2023 TD ()Tj .5185 -.2023 TD [(NAY)-332.3(ET)-338.7(AL.)]TJ ET endstream endobj 56 0 obj <>stream h,P=kTAݷ8縷؈Vj;-D슻lg̛yA AT^஦q{N{I ۸}ΕLWNygWOΝ,~t`u{yqU4D#8 1(31DaM# !:B[eE-;z>'HEzkŎ64iR/ګζ 7fukڦ2cg"*$+SٙCZbe>^9m5Zo=:`'SZ@cL0#^ kba;f> ٺfVүU+pҁ[)M-'9z'hg6{ ^9%yBx"Mi:XaD쭂·#3Ȟ_.UM@3N endstream endobj 57 0 obj <> endobj 58 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 62 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 63 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 59 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 59.7543 498.2739 Tm 0 0 0 1 k 0 Tc 0 Tw [(comparison)-644.5(of)-641.9(antibody)-641.2(titers)-645(were)-640.7(performed)-638.7(by)-641.1(SPSS)]TJ 0 -1.2203 TD [(package)-286.6(version)-277.9(17.0)-279.7(\(SPSS)-288.1(Inc.\).)]TJ /F3 1 Tf 0 -2.8896 TD (Results)Tj /F10 1 Tf 0 -1.8336 TD [(Detection)-340.2(of)-330.4(SFV/TOSV)-338.3(IgG)-333.5(and)-329.4(IgM)-338.4(seroreactivity)]TJ 0 -1.2203 TD [(by)-332.7(commercial)-340.4(assays)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(The)-366.7(distribution)-376.2(of)-363.6(positive/equivocal/tested)-381.2(results)-369(and)]TJ -1.1128 -1.2203 TD [(antibody)-350.3(titers)-341.5(for)-345.4(SFV)-347.2(serotypes)-347.3(according)-344.7(to)-344.7(the)-345.2(IIFT)-346.8(sub-)]TJ 0 -1.2267 TD [(strate)-267.9(are)-265.7(given)-258.6(in)-266.2(Table)-263.3(2.)-261.7(Overall)-263.9(rate)-266.1(of)-262.5(equivocal/positive)]TJ 0 -1.2203 TD [(results)-236.2(from)-229.1(TOSV)-228.6(IIFT)-226.6(and)-227.2(ELISA)-229.3(were)-229.7(18/53)-228.7(\(total:)-231.4(71/120;)]TJ T* [(59.2%\))-357.6(and)-353.7(10/8)-349.3(\(total:18/120;)-361.4(15%\),)-351.8(respectively.)-359.4(Positive/)]TJ 0 -1.2266 TD [(strong)-202.7(positive)-203.3(results)-204.6(from)-197.5(TOSV)-203.4(IgG)-195(IB)-201.1(were)-198.1(9/43)-197.5(\(total:52/)]TJ 0 -1.2203 TD [(120;)-298.6(43.3%\))-294.4(\(Table)-295.4(2\).)-293.8(No)-299.9(reactivity)-297.1(for)-294.8(Hantavirus)-301.4(serotypes)]TJ T* [(was)-280.7(observed)-284.6(in)-285.1(any)-279.2(of)-281.4(the)-282(IB)-277(reactive)-282.2(samples.)]TJ 1.1128 -1.2203 TD [(For)-343(SFV)-340.8(IgM,)-337(a)-340.9(total)-341.9(of)-338.4(eight)-340.5(samples)-345.9(\(8/120,)-339.6(6.7%\))-339.2(were)]TJ -1.1128 -1.2266 TD [(reactive)-294.9(\(positive)-292.3(or)-288(equivocal\))-287.4(in)-291.4(the)-288.3(IIFT)-283.5(\(Table)-289(2\).)-287.4(The)-290.8(dis-)]TJ 0 -1.2203 TD [(tribution)-273.6(of)-262.5(SFV)-271.3(serotypes)-265.1(identied)-272.6(was)-261.7(SFNV)-271.3(in)-266.2(3,)-261.7(SFSV)-269.8(in)]TJ T* [(2,)-350.2(TOSV)-355.1(in)-348.4(1,)-350.2(and)-353.7(SFSV)]TJ /F11 1 Tf 10.7173 0 TD ()Tj /F5 1 Tf .7714 0 TD [(SFCV)-353.6(in)-348.4(1)-353.6(sample.)-347.5(IgM)-353.1(IIFT)-346.8(titers)]TJ -11.4887 -1.2267 TD [(observed)-215.1(are)-208.8(given)-214.3(in)-209.2(Table)-206.4(2.)-211.1(All)-210.8(samples)-206.8(were)-210.8(negative)-214.2(with)]TJ 0 -1.2203 TD [(the)-541.2(TOSV)-538.5(IgM)-536.5(ELISA,)-535.7(and)-537(one)-543.5(SFNV)-536.8(IgM)-536.4(IIFT)-536.5(reactive)]TJ T* [(sample)-294(was)-293.3(positive)-291.8(in)-297.8(TOSV)-291.9(IgG)-289.8(ELISA.)-295.4(IB)-289.6(assay)-290.6(for)-294.8(TOSV)]TJ 0 -1.2266 TD [(IgM)-283.5(was)-280.7(not)-278.5(performed.)]TJ /F10 1 Tf 0 -2.8896 TD [(VNT)-335.2(results)]TJ /F5 1 Tf 1.1128 -1.8273 TD [(VNTs)-329.6(for)-332.7(SFSV,)-335.9(SFNV,)-331.1(and)-328.4(TOSV)-329.8(were)-330.9(performed)-335.2(for)-332.7(99)]TJ -1.1128 -1.2266 TD [(samples,)-279.3(excluding)-279.8(21)-277.2(due)-276.1(to)-281.4(insufcient)-278.9(amounts.)-281.2(A)-273.3(total)-278.6(of)]TJ 0 -1.2203 TD [(31)-441.6(samples)-440.8(\(31/99;)-440.7(31.3%\))-439.8(were)-438.4(reactive)-446.6(in)-436.9(the)-440(VNTs)-443.4(that)]TJ T* [(comprise)-449(15)-441.6(TOSV)-443.6(\(15.2%\),)-443.2(11)-441.6(SFSV)-446.8(\(11.1%\),)-443.2(and)-442.2(3)-442.1(SFNV)]TJ 0 -1.2266 TD [(\(3.03%\))-478.2(\(Table)-478.7(3\).)-483.4(Two)-475.3(samples)-478.7(were)-482.7(observed)-480.6(to)-477.5(possess)]TJ 0 -1.2203 TD [(neutralizing)-320.4(antibodies)-319(for)-320.1(more)-317.1(than)-316.6(one)-322.2(SFV)-315.5(serotype)-320.7(and)]TJ T* [(displayed)-411.6(reactivity)-410.9(for)-408.6(SFSV)-408.9(and)-404.2(SFNV)-410.4(where)-410.2(the)-408.4(titer)-409.7(of)]TJ 0 -1.2266 TD [(SFSV)-295(\(1/320\))-292.8(exceeded)-291.6(that)-294.7(of)-294.1(SFNV)-290.2(\(1/40)-292.9(and)-290.4(1/80\))-292.9(\(Table)]TJ 0 -1.2203 TD [(3\).)-287.4(None)-284.2(of)-281.4(the)-288.3(IgM-positive)-291.3(samples)-282.7(were)-286.7(reactive)-282.2(in)-285.1(VNTs,)]TJ T* [(and)-410.6(for)-414.9(the)-408.4(sample)-414.2(with)-407.4(SFSV)]TJ /F11 1 Tf 13.7966 0 TD ()Tj /F5 1 Tf .7714 0 TD [(SFCV)-410.6(IgM)-410(positivity,)-417.1(VNT)]TJ -14.568 -1.2266 TD [(was)-350.2(not)-341.7(performed.)-350.7(The)-347.7(presence)-347.2(of)-344.7(neutralizing)-352(antibodies)]TJ 0 -1.2203 TD [(for)-465.5(TOSV)-462.6(could)-458.9(be)-459.6(demonstrated)-467.2(in)-462.2(15)-454.3(of)-464.8(the)-459(89)-460.6(samples)]TJ T* [(\(16.9%\))-275.9(reactive)-282.2(in)-272.5(any)-279.2(of)-275.1(the)-275.6(commercial)-281.9(assays)-272.9(and)-277.8(in)-278.8(15)-270.9(of)]TJ T* [(60)-340.5(samples)-339.6(\(25%\))-336.7(reactive)-345.5(with)-337.8(TOSV)-336.1(IIFT.)-337(In)-340.6(samples)-339.6(with)]TJ 0 -1.2266 TD [(IIFT)-504.8(reactivity)-505.7(other)-500.4(than)-506.3(TOSV,)-497.1(41.9%)-502.6(\(13/31\))-501.5(and)-499.1(9.7%)]TJ 28.0042 49.167 TD [(\(3/31\))-407.1(were)-413.1(positive)-412(in)-411.6(VNTs)-411.8(for)-408.6(SFSV)-415.2(and)-404.2(SFNV,)-413.3(respec-)]TJ 0 -1.2203 TD [(tively)-278.2(\(Table)-282.7(3\).)]TJ /F10 1 Tf 0 -2.624 TD [(Evaluation)-333.2(of)-336.7(TOSV)-333.3(commercial)-334.1(assays)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(A)-412.4(total)-417.7(of)-420.6(31)-416.3(samples)-415.5(\(31/120;)-421.3(25.8%\))-414.5(were)-419.4(observed)-417.4(as)]TJ -1.1128 -1.2203 TD [(negative)-277.4(for)-269.5(TOSV)-272.9(IgG)-277.2(and)-271.5(89)-270.9(samples)-276.4(\(89/120;)-275.8(74.2%\))-269.1(were)]TJ T* [(reactive)-244.3(in)-240.9(at)-240.2(least)-245(one)-246.3(of)-237.2(the)-244(commercial)-243.9(assays)-241.3(\(positive)-248(and)]TJ 0 -1.2266 TD [(equivocal)-426(results)-425.9(interpreted)-430.6(as)-424.5(reactive\).)-431.1(Thirteen)-431.6(samples)]TJ 0 -1.2203 TD [(\(13/89;)-598.8(14.6%\))-597.9(were)-596.5(reactive)-604.7(in)-601.3(all)-594.6(assays.)-604.7(Reactivity)-597.8(in)]TJ T* (IIFT)Tj /F11 1 Tf 1.821 0 TD ()Tj /F5 1 Tf .7714 0 TD [(IB)-213.8(and)-220.9(IIFT)]TJ /F11 1 Tf 4.8686 0 TD ()Tj /F5 1 Tf .7714 0 TD [(ELISA)-216.7(only)-216.4(were)-217.1(noted)-224.5(in)-215.6(25)-214(\(28.1%\))-219(and)-214.6(2)]TJ -8.2324 -1.2203 TD [(\(2.2%\))-181.6(samples,)-190.8(respectively.)-188.7(For)-184.9(equivocal)-185.8(samples)-187.9(in)-184(IIFT,)-185.3(12)]TJ 0 -1.2266 TD [(out)-402.9(of)-407.9(18)-397.4(were)-406.8(observed)-404.8(as)-405.5(negative)-410.2(in)-398.9(ELISA)-406.3(or)-408.1(IB.)-400.1(In)-403.8(49)]TJ 0 -1.2203 TD [(samples)-314.3(\(49/89;)-314.3(55.1%\),)-310(reactivity)-322.4(was)-312.3(observed)-316.2(via)-313.6(a)-309.3(single)]TJ T* [(assay)-353.8(\(31)-353.6(in)-354.7(IIFT,)-356(14)-353.1(in)-361(IB,)-349.5(and)-360(4)-353.6(for)-358(ELISA\).)-352.8(No)-356.8(signicant)]TJ 0 -1.2267 TD [(correlation)-225.2(among)-222.6(IIFT)-226.6(titers,)-224.3(ELISA)-223(optical)-225.4(densities,)-227.9(and/or)]TJ 0 -1.2203 TD [(VNT)-277.7(titers)-284.6(could)-281.8(be)-282.5(demonstrated)-283.9(\(data)-281.2(not)-284.8(shown\).)]TJ 1.1128 -1.2203 TD [(Agreement)-285.8(among)-285.9(commercial)-288.2(assays,)-282.2(assessed)-292.1(via)-282(kappa)]TJ -1.1128 -1.2266 TD [(coefcient,)-482.8(was)-476.7(observed)-480.6(as)-475(slight)-484.6(to)-477.5(fair,)-475(and)-480.1(percentage)]TJ 0 -1.2203 TD [(agreement)-593.8(values)-594.4(were)-596.5(calculated)-597.4(as)-595.2(50%63%)-588.8(\(average:)]TJ T* [(57.8%\))-420.9(\(Table)-428.1(4\).)-426.5(When)-423(results)-425.9(from)-425.1(all)-423.9(commercial)-427.3(assays)]TJ T* (\(IIFT)Tj /F11 1 Tf 2.1435 0 TD ()Tj /F5 1 Tf .7714 0 TD (ELISA)Tj /F11 1 Tf 2.8327 0 TD ()Tj /F5 1 Tf .7714 0 TD [(IB\))-182.6(were)-191.8(evaluated)-185(via)-187.1(Fleiss)-191.1(kappa,)-186.1(the)-187.1(overall)]TJ -6.5189 -1.2266 TD [(agreement)-302.9(was)-306(noted)-306.7(as)-304.3(slight)-307.5(\(K:)-303.4(0.116\).)-307.9(The)-303.5(agreement)-309.2(be-)]TJ 0 -1.2203 TD [(tween)-213.9(VNT)-214.5(and)-214.6(the)-218.7(commercial)-218.6(assays)-216(was)-211.1(slight)-219(to)-218.2(fair,)-209.5(with)]TJ T* [(percentage)-204.8(agreement)-208.1(values)-208.7(between)-205.6(53%)-203(and)-201.9(82%)-203(\(average:)]TJ 0 -1.2266 TD [(62.6%\))-364(\(Table)-364.9(4\).)-369.6(Fleiss)-368.1(kappa)-366.6(for)-364.3(VNT)-366.2(and)-366.3(the)-364.2(commercial)]TJ 0 -1.2203 TD [(assays)-279.3(also)-279(displayed)-285.1(slight)-282.2(agreement)-284(\(K:)-284.4(0.151\).)]TJ /F3 1 Tf 0 -2.5545 TD (Discussion)Tj /F5 1 Tf 1.1128 -1.8336 TD [(TOSV)-513.2(is)-510.7(one)-511.9(of)-515.4(the)-515.9(major)-511.3(viral)-513.9(pathogens)-516(involved)-517.1(in)]TJ -1.1128 -1.2203 TD [(aseptic)-593.4(meningoencephalitis)-596.8(occurring)-590.8(during)-591.8(summer)-586.4(in)]TJ 0 -1.2266 TD [(Mediterranean)-215(countries)-221.4(and)-208.2(poses)-215.3(a)-214.5(threat)-213.1(to)-218.2(the)-212.4(residents)-215.8(as)]TJ 0 -1.2203 TD [(well)-318.4(as)-323.3(the)-326.2(travelers)-322.9(\(Eitrem)-328.1(et)-322.8(al.)-322.1(1991b,)-315.2(Charel)-329.7(et)-322.8(al.)-315.8(2005\).)]TJ T* [(Due)-363.1(to)-357.3(the)-364.2(frequent)-364.7(co-circulation)-367.6(of)-357.3(various)-364(SFV)-359.8(serotypes)]TJ 0 -1.2266 TD [(that)-503.3(cross-react)-498.9(in)-500.1(serological)-508.1(assays,)-497.2(the)-503.3(detection)-505.9(of)-496.4(im-)]TJ 0 -1.2203 TD [(mune)-267.8(responses)-271.2(to)-262.5(TOSV)-266.6(can)-267.7(be)-263.6(challenging)-268.6(\()-82.7(Magurano)-269.7(and)]TJ T* [(Nicoletti)-399.2(1999,)-393(Dionisio)-401.6(et)-392.4(al.)-398(2003\).)-393.5(Although)-400.1(a)-397.9(number)-399.3(of)]TJ 0 -1.2266 TD [(commercial)-389.3(assays)-393.1(have)-389.2(been)-393.3(developed)-393.5(for)-389.6(the)-389.5(serological)]TJ 0 -1.2203 TD [(detection)-468(of)-458.5(TOSV)-462.6(exposure,)-467.6(data)-464.1(on)-461.4(the)-465.3(performances)-468.4(of)]TJ T* [(these)-321.1(assays)-317.2(have)-313.4(not)-322.8(been)-317.4(available.)-314.3(In)-321.6(this)-318.5(study,)-317(we)-317.7(eval-)]TJ 0 -1.2266 TD [(uated)-301.4(the)-300.9(most)-299.3(widely)-300.5(used)-302.7(commercial)-300.8(assays)-298.2(for)-301.1(detecting)]TJ ET 59.754 720.113 490.167 .22681 re f 59.754 562.79 490.167 .22675 re f 59.754 701.121 490.167 .22675 re f BT /F7 1 Tf 8.9663 0 0 8.9663 117.8078 725.7825 Tm (Table)Tj /F5 1 Tf 3.0603 0 TD (1.)Tj /F7 1 Tf 1.2519 0 TD [(General)-334.1(Characteristics)-337.2(of)-336.4(the)-332(Commercial)-337.4(Assays)-336.5(Evaluated)-334.7(in)-328.8(the)-338.4(Study)]TJ /F8 1 Tf 5.9751 -2.0423 TD [(IIFT)-13874.5(ELISA)-12863.3(IB)]TJ /F5 1 Tf -16.762 -2.0992 TD [(Manufacturer)-4033.1(Euroimmun)-340(Labordiagnostika)-333.5(AG)-2415.5(Diesse)-336.1(Diagnostica)-6335.7(Mikrogen)-334.1(Diagnostik)]TJ 0 -1.1065 TD [(Assay)-336.7(format)-4111.4(Immunouorescent)-345.6(assay)-6316.3(Enzyme)-336.6(immunoassay)-4634.3(Strip)-333.3(immunoassay)]TJ 0 -1.1128 TD [(Antigen)-339(source)-3331.2(Cell)-335.9(culture)-335.4(grown)-335.4(viruses)-5813.3(Recombinant)-340.9(N)-328.8(protein)-4223.2(Recombinant)-334.6(N)-335.1(protein)]TJ T* [(Target)-7216.1(TOSV)-336.1(IgM/IgG)-336.1(SFSV,)-335.9(SFNV,)]TJ 11.0461 -1.1128 TD [(SFCV)-334.7(IgM/IgG)]TJ 16.6419 1.1128 TD [(TOSV)-336.1(IgM/IgG)-7632.7(TOSV)-329.8(IgM/IgG)-336.1(Hantavirus)]TJ 15.6619 -1.1128 TD (IgM/IgG)Tj -43.3499 -1.1065 TD [(Sample)-6810.1(Serum/plasma)-11031(Serum/plasma)-8052.9(Serum/plasma)]TJ 0 -1.1128 TD [(Turnaround)-341.6(time)]TJ /F14 1 Tf 10.0471 0 TD (*)Tj /F5 1 Tf .999 0 TD [(1)-170.2(h)-332.2(15)-169.7(min)]TJ /F14 1 Tf 16.6419 0 TD (*)Tj /F5 1 Tf .999 0 TD [(1)-170.2(h)-332.2(50)-163.4(min)]TJ /F14 1 Tf 13.6638 0 TD (*)Tj /F5 1 Tf .999 0 TD [(4)-163.9(h)-338.5(45)-163.4(min)]TJ -43.3499 -1.1128 TD [(Hands-on)-342.6(time)]TJ /F14 1 Tf 10.0471 0 TD (*)Tj /F5 1 Tf .999 0 TD [(15)-169.7(min)]TJ /F14 1 Tf 16.6419 0 TD (*)Tj /F5 1 Tf .999 0 TD [(15)-169.7(min)]TJ /F14 1 Tf 13.6638 0 TD (*)Tj /F5 1 Tf .999 0 TD [(45)-163.4(min)]TJ -43.3499 -1.1128 TD [(Interpretation)-3983.1(Fluorescent)-339.5(microscopy)-7208.5(Optic)-336.5(density)-338.5(measurement)-2416.9(Visual)]TJ 0 -1.1065 TD (Sensitivity)Tj 6.7246 0 0 5.9768 100.8567 602.9857 Tm (a)Tj 8.9663 0 0 8.9663 149.8393 599.0172 Tm [(Not)-338.3(available)-11692.6(100%)-335.3(\(IgM\))-9528.6(100%)-329(\(IgM\))]TJ 17.6409 -1.1128 TD [(95.0%)-331.9(\(IgG\))-9459(100%)-329(\(IgG\))]TJ -27.688 -1.1128 TD (Specicity)Tj 6.7246 0 0 5.9768 100.1196 583.0865 Tm (a)Tj 8.9663 0 0 8.9663 149.8393 579.0613 Tm [(Not)-338.3(available)-11692.6(100%)-335.3(\(IgM\))-9528.6(99%)-329.4(\(IgM\))]TJ 17.6409 -1.1065 TD [(96.5%)-331.9(\(IgG\))-9459(99%)-329.4(\(IgG\))]TJ 5.9774 0 0 5.3127 67.748 554.5132 Tm (a)Tj 7.9702 0 0 7.9702 70.7527 550.9983 Tm [(As)-329.1(provided)-322.4(by)-332.9(the)-330.9(manufacture)11.6(r.)]TJ -.377 -1.1239 TD [(IIFT,)-246.9(indirect)-249.3(immunou)11.7(orescence)-246.6(test;)-256.4(ELISA,)-240.9(enzyme-linked)-242.5(immunosorb)11.6(ent)-252.7(assay;)-246.8(IB,)-249.9(immunoblo)10.9(t;)-253.1(TOSV,)-249.7(Toscana)-242.7(virus;)-251.6(SFSV,)-249.7(Sicilian)]TJ -1.003 -1.131 TD [(virus;)-329.8(SFNV,)-331.8(sandy)-322.8(fever)-327.3(Naples)-334.3(virus;)-322.7(SFCV,)-332(sandy)-322.8(fever)-334.4(Cyprus)-323.8(virus.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(SERODIAGNOSIS)-341.6(OF)-331.2(TOSCANA)-340.3(VIRUS)-333.8(EXPOSURE)-28299.6(783)]TJ ET endstream endobj 64 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 67 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 68 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 65 0 obj <>stream 0 0 0 1 k /GS1 gs 186.633 57.317 .28346 700.214 re f 409.833 57.317 .22681 700.214 re f 205.909 148.649 .28346 365.216 re f 1 i q 1 0 0 1 205.909 513.864 cm 0 0 m 0 88.157 l .283 88.157 l .283 0 l f* Q 205.909 602.022 .28346 155.509 re f 243.836 148.649 .22676 365.216 re f q 1 0 0 1 243.836 513.864 cm 0 0 m 0 88.157 l .227 88.157 l .227 0 l f* Q 243.836 602.022 .22676 155.509 re f 261.524 57.317 .22678 700.214 re f BT /F7 1 Tf 0 8.9663 -8.9663 -0 171.2692 161.9716 Tm 0 Tc 0 Tw (Table)Tj /F5 1 Tf 3.0603 0 TD (2.)Tj /F7 1 Tf 1.2519 0 TD [(Distribution)-338(of)-330(Indirect)-338.1(Immunouorescence)-339(Test,)-332(Enzyme-Linked)-338.7(Immunosorbent)-337.9(Assay,)-331.1(Immunoblot,)]TJ 5.4251 -1.1065 TD [(and)-331.7(Virus)-339.4(Neutralization)-331.8(Test)-335.4(Results)-334.7(According)-335.5(to)-334(the)-338.4(Serum)-333.6(Panels)]TJ /F8 1 Tf -.3983 -2.0486 TD [(IIFT)-337.1(IgG)-16581.5(IIFT)-337.1(IgM)-6365.9(TOSV)-334.1(ELISA)-337.6(IgG)-2089.4(TOSV)-334.1(IB)-332.3(IgG)-4991.6(VNT)]TJ /F5 1 Tf 0 6.7246 -5.9768 -0 195.5338 722.6077 Tm (a)Tj /F8 1 Tf 0 8.9663 -8.9663 -0 227.5086 192.8692 Tm (Positive/equivocal)Tj /F5 1 Tf 0 6.7246 -5.9768 -0 223.4834 257.329 Tm (b)Tj /F8 1 Tf 0 8.9663 -8.9663 -0 227.5086 261.0141 Tm [(/tested)-337.5(\(titer)-339.8(range)]TJ -5.1468 -1.1065 TD [(for)-337(positive)-332.7(samples)-339.3([1/x]\))]TJ 20.3851 2.2193 TD (Positive/equivocal)Tj /F5 1 Tf 0 6.7246 -5.9768 -0 213.5621 462.0471 Tm (b)Tj /F8 1 Tf 0 8.9663 -8.9663 -0 217.5306 465.7889 Tm (/tested)Tj -7.0564 -1.1128 TD [(\(titer)-339.8(range)-333.4(for)-330.7(positive)]TJ 1.8526 -1.1065 TD [(samples)-339.3([1/x]\))]TJ 11.2421 2.2193 TD (Positive/equivocal/)Tj -.6765 -1.1128 TD [(tested)-337.7(\(ratio)-337.2(positive\)/)]TJ 1.1444 -1.1065 TD [(\(ratio)-330.9(equivocal\))]TJ 10.6794 2.2193 TD (Strong)Tj -1.9917 -1.1128 TD (positive/positive/)Tj 2.213 -1.1065 TD [(tested)-5136.7(Positive/tested)]TJ -62.9635 -2.0107 TD [(Panel)-9544.2(SFSV)-4100.7(SFNV)-3958.5(TOSV)-4020.4(SFCV)-2652.5(SFSV)-1103.6(SFNV)-999.4(TOSV)-1048.6(SFCV)-18605.2(SFSV)-1002.4(SFNV)-999.4(TOSV)]TJ /F6 1 Tf 0 -2.0929 TD (1)Tj /F5 1 Tf .8346 0 TD (\(n:18\))Tj /F6 1 Tf 10.6035 0 TD (12/6/18)Tj /F5 1 Tf 7.5622 0 TD [(0/18)-4724.8(0/18)-4231.6(0/18)-2726.7(0/18)-1481.1(0/18)-1519(0/18)-1506.4(0/18)]TJ /F6 1 Tf 35.0416 0 TD [(1/1/18)-6447.1(0/3/18)-2868.4(10/17)-1597.6(1/17)]TJ /F5 1 Tf 21.6749 0 TD (0/17)Tj -75.7169 -1.1128 TD [(\(SFSV)-339.8(IIFT)-334.1(reactive\))-1781.2(\(3201000\))]TJ 53.1377 0 TD (\(1.3\)/\(1.2\))Tj /F6 1 Tf -53.1377 -1.1065 TD (2)Tj /F5 1 Tf .8346 0 TD [(\(n:11\))-9117.6(0/11)]TJ /F6 1 Tf 17.6852 0 TD (7/4/11)Tj /F5 1 Tf 7.3093 0 TD [(0/11)-4231.6(0/11)-2726.7(0/11)]TJ /F6 1 Tf 14.2771 0 TD (0/2/11)Tj /F5 1 Tf 4.0972 0 TD [(0/11)-1506.4(0/11)-4364.3(0/11)]TJ /F6 1 Tf 18.8676 0 TD (5/4/11)Tj /F5 1 Tf 5.6337 0 TD (0/10)Tj /F6 1 Tf 3.7052 0 TD (3/10)Tj /F5 1 Tf 3.3069 0 TD (0/10)Tj -75.7169 -1.1128 TD [(\(SFNV)-335(IIFT)-334.1(reactive\))-8066.2(\(3201000\))]TJ /F6 1 Tf T* (3)Tj /F5 1 Tf .8346 0 TD [(\(n:46\))-9117.6(0/46)-4478.2(0/46)]TJ /F6 1 Tf 23.5149 0 TD (31/15/46)Tj /F5 1 Tf 7.8151 0 TD (0/46)Tj /F6 1 Tf 4.3502 0 TD (1/1/46)Tj /F5 1 Tf 4.0656 0 TD [(0/46)-1519(0/46)-1506.4(0/46)]TJ /F6 1 Tf 13.4615 0 TD [(0/4/46)-5947.6(13/1/46)]TJ /F5 1 Tf 14.6628 0 TD [(0/45)-1291.4(0/45)]TJ /F6 1 Tf 6.696 0 TD (11/45)Tj /F5 1 Tf -75.4007 -1.1128 TD [(\(TOSV)-336.6(IIFT)-334.1(reactive\))-14635.7(\(3201000\))-8273.7(\(320\))-14630.7(\(0.80.9\))]TJ /F6 1 Tf 0 -1.1065 TD (4)Tj /F5 1 Tf .8346 0 TD [(\(n:7\))-9541.7(0/7)-4978.2(0/7)-5199.5(0/7)]TJ /F6 1 Tf 31.349 0 TD (3/4/7)Tj /F5 1 Tf 4.8244 0 TD [(0/7)-2094.9(0/7)-1955.8(0/7)-2120.2(0/7)]TJ /F6 1 Tf 17.2868 0 TD (0/1/7)Tj /F5 1 Tf 9.0165 0 TD [(0/7)-3947.5(0/7)-1879.9(0/7)-1791.4(0/7)]TJ -63.3113 -1.1128 TD [(\(SFCV)-335.1(IIFT)-334.1(reactive\))-22982(\(320\))-20207.5(\(0.8\))]TJ /F6 1 Tf T* (5)Tj /F5 1 Tf .8346 0 TD (\(n:13\))Tj /F6 1 Tf 10.6035 0 TD (12/1/13)Tj /F5 1 Tf 7.5622 0 TD [(0/13)-4724.8(0/13)]TJ /F6 1 Tf 12.1842 0 TD [(12/1/13)-2248.2(0/1/13)]TJ /F5 1 Tf 9.3959 0 TD [(0/13)-1519(0/13)]TJ /F6 1 Tf 6.7592 0 TD [(0/1/13)-4120.3(1/0/13)-6447.1(1/1/13)-3367.9(3/5)-2079.1(1/5)]TJ /F5 1 Tf 28.4594 0 TD (0/5)Tj -75.7991 -1.1065 TD (\(SFSV)Tj /F11 1 Tf 2.6367 0 TD ()Tj /F5 1 Tf .7714 0 TD [(SFSV)-333(IIFT)]TJ -2.409 -1.1128 TD (reactive\))Tj 9.1872 1.1128 TD (\(320)Tj /F12 1 Tf 2.4912 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000\))-14161.8(\(320)]TJ /F12 1 Tf 18.9751 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000\))-18872.4(\(1.3\))]TJ /F6 1 Tf -33.1953 -2.2257 TD (6)Tj /F5 1 Tf .8346 0 TD [(\(n:25\))-9117.6(0/25)]TJ /F6 1 Tf 17.1857 0 TD [(18/7/25)-3746.8(22/3/25)]TJ /F5 1 Tf 14.1444 0 TD [(0/25)-2726.7(0/25)]TJ /F6 1 Tf 7.9416 0 TD [(0/1/25)-1034.7(0/1/25)]TJ /F5 1 Tf 7.7076 0 TD (0/25)Tj /F6 1 Tf 6.2281 0 TD [(6/4/25)-5947.6(24/0/25)]TJ /F5 1 Tf 14.6628 0 TD [(0/15)-1291.4(0/15)]TJ /F6 1 Tf 7.1702 0 TD (4/15)Tj /F5 1 Tf -75.8749 -1.1128 TD (\(SFNV)Tj /F11 1 Tf 2.9402 0 TD ()Tj /F5 1 Tf .7714 0 TD [(TOSV)-329.8(IIFT)]TJ -2.7125 -1.1065 TD (reactive\))Tj 15.7693 1.1065 TD (\(320)Tj /F12 1 Tf 2.4912 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000\))-997.5(\(320)]TJ /F12 1 Tf 5.8108 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000\))-22451.2(\(1.33.7\)/\(0.91.1\))]TJ 0 7.9702 -7.9702 -0 421.8519 65.3102 Tm [(Pos)6.4(itive)-333.8(samp)8.2(les)-335.9(in)-327.8(bold.)]TJ 0 5.9774 -5.3127 -0 427.2944 65.3102 Tm (a)Tj 0 7.9702 -7.9702 -0 430.8093 68.2583 Tm [(Perform)5.3(ed)-336.4(for)-331.1(99)-330.2(samp)8.2(les.)]TJ 0 5.9774 -5.3127 -0 436.2519 65.3102 Tm (b)Tj 0 7.9702 -7.9702 -0 439.7668 68.5984 Tm [(Titer:)-329(1:10)7.3(0.)]TJ -.4126 -1.131 TD [(VNT,)-330.3(v)7.2(irus)-330.9(neutral)5.4(ization)-332(test)5.8(.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 299.6786 34.9228 Tm (784)Tj ET endstream endobj 69 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 71 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 72 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 70 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 59.7543 303.8173 Tm 0 0 0 1 k 0 Tc 0 Tw [(TOSV)-253.9(immunoglobulins.)-258.7(In)-252.1(addition,)-256.1(a)-252.4(signicant)-255.8(number)-253.9(of)]TJ 0 -1.2203 TD [(the)-364.2(samples)-358.6(\(99/120;)-358(82.5%\))-357.6(were)-356.2(investigated)-367.9(for)-358(the)-357.8(pres-)]TJ T* [(ence)-280.7(of)-281.4(neutralizing)-282.5(antibodies)-281.1(to)-275.1(SFSV,)-279(SFNV,)-280.5(and)-277.8(TOSV)-279.2(as)]TJ 0 -1.2267 TD [(well.)-264.4(Since)-263.8(IgM)-258.2(for)-263.2(TOSV)-260.3(and)-258.8(other)-266.5(SFVs)-259.9(were)-261.4(only)-260.7(detected)]TJ 0 -1.2203 TD [(in)-361(a)-359.9(small)-359.5(number)-361.4(of)-363.6(samples)-358.6(in)-361(the)-364.2(study)-358.3(group)-364.7(via)-357.9(IIFT/)]TJ T* [(ELISA)-286.2(\(n:8\))-285(and)-284.1(VNTs)-279(were)-286.7(observed)-284.6(to)-281.4(be)-282.5(negative,)-286.7(we)-279.7(did)]TJ T* [(not)-386(perform)-382.8(the)-389.5(IB)-378.2(assay)-385.4(for)-383.3(IgM)-378.4(reactive)-389.7(samples)-383.9(or)-382.8(com-)]TJ 0 -1.2267 TD [(pared)-257.4(IgM)-251.9(results.)-258.1(This)-251.5(constitutes)-260.9(the)-256.7(main)-256.9(limitation)-252.3(of)-256.2(this)]TJ 0 -1.2203 TD [(study.)-190.5(Nevertheless,)-191(viral)-185.1(RNA)-189(detection)-189.8(has)-187.6(been)-184.6(established)]TJ T* [(as)-272.7(a)-265.1(powerful)-271(tool)-275.1(and)-265.1(an)-268.5(effective)-276.5(alternative)-270.9(for)-269.5(identifying)]TJ 0 -1.2266 TD [(acute)-240.8(TOSV)-235(infections)-239.3(\(Charel)-235.3(et)-234.3(al.)-233.6(2005\).)-235.4(The)-233.9(impact)-235.7(of)-237.2(viral)]TJ 0 -1.2203 TD [(RNA)-429.2(detection)-423.7(in)-424.2(TOSV-associated)-429.4(central)-424.1(nervous)-427.5(system)]TJ 28.0042 13.4425 TD [(infections)-334.2(in)-335.7(the)-332.5(study)-333(region)-337.2(has)-333(also)-329.6(been)-336.4(documented)-333.1(re-)]TJ 0 -1.2203 TD [(cently,)-418.6(where)-422.8(TOSV)-418.3(IgM)-416.3(was)-419.8(identied)-424.4(via)-414.8(IIFT)-422.6(in)-417.9(only)-418.8(4)]TJ T* [(\(25%\))-216.6(of)-211.9(the)-218.7(16)-214(TOSV)-216(RNA)-214.3(positive)-222.3(sera)-216.4(\(Ergu)]TJ 19.5315 .0063 TD ()Tj .4742 -.0063 TD [(nay)-209.7(et)-215.3(al.)-214.6(2010\).)]TJ -18.8929 -1.2267 TD [(For)-444.2(TOSV)-443.6(IgG,)-444.5(the)-452.7(commercial)-446.3(assays)-443.7(evaluated)-450.5(in)-443.2(this)]TJ -1.1128 -1.2203 TD [(study)-282.4(were)-280.3(observed)-284.6(to)-281.5(display)-282.2(slight)-282.2(to)-281.4(fair)-282.4(agreement)-284(with)]TJ T* [(an)-179.9(average)-181.7(percentage)-185.9(of)-180.3(57.8%.)-183(This)-181.9(relatively)-180.6(low)-185(agreement)]TJ T* [(observed)-316.2(is)-314.7(presumably)-323.9(due)-314.1(to)-319.4(the)-313.6(viral)-317.8(antigens)-319.4(employed,)]TJ 0 -1.2267 TD [(as)-399.2(well)-400.6(as)-399.2(differences)-403.9(in)-398.9(assay)-398.1(congurations,)-408.2(as)-399.2(displayed)]TJ 0 -1.2203 TD [(previously)-184(\(Calisher)-183.2(et)-183.7(al.)-183(1999,)-178(Cusi)-183.4(et)-183.7(al.)-176.7(2001,)-184.3(Di)-182(Bonito)-180.3(et)-183.7(al.)]TJ T* [(2002\).)-229.1(While)-237(virus-infected)-239.4(cells)-235.2(are)-234.1(the)-231.4(source)-232.9(of)-237.2(the)-231.4(antigens)]TJ 0 -1.2266 TD [(in)-398.9(the)-402.1(IIFT,)-400.3(recombinant)-400.6(N)-398.3(protein)-404.1(of)-401.6(TOSV)-399.4(is)-403.2(used)-397.6(in)-398.9(the)]TJ 0 -1.2203 TD [(ELISA)-267.2(and)-265.1(IB,)-267.3(although)-271.8(in)-266.2(different)-277.4(matrices.)-264.4(The)-271.9(TOSV)-266.6(IIFT)]TJ ET 59.811 720.057 490.11 .22675 re f 59.811 365.442 490.11 .22675 re f 124.611 700.781 172.913 .22681 re f 432.567 700.781 117.354 .22681 re f 59.811 683.093 490.11 .22675 re f BT /F7 1 Tf 8.9663 0 0 8.9663 138.0472 725.7258 Tm (Table)Tj /F5 1 Tf 3.0603 0 TD (3.)Tj /F7 1 Tf 1.2519 0 TD [(Assay)-334.5(Results)-334.7(for)-334.5(the)-332(Virus)-339.4(Neutralization)-331.8(Test)-335.4(Reactive)-335.5(Samples)]TJ /F8 1 Tf .3351 -2.0423 TD [(IIFT)-337.2(\(titer:)-336.4([1/x]\))-24122.2(VNT)-329.7(\(titer:)-336.4([1/x]\))]TJ -13.373 -2.0044 TD [(Sample)-336(no.)-2934.1(SFSV)-3025.8(SFNV)-2883.7(TOSV)-2945.5(SFCV)-2873.8(ELISA)-337.6(\(ratio\))-2911.1(IB)-2905.7(SFSV)-2741.2(SFNV)-2738.2(TOSV)]TJ /F5 1 Tf 0 -2.0992 TD [(1)-7821(n)-5106(320)-3836.5(n)-4935.3(n)-5504.3(0.459)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD [(n)-4182.8(160)-4317.1(n)]TJ -42.4773 -1.1065 TD [(2)-7821(n)-5106(320)-3836.5(n)-4935.3(n)-5504.3(0.391)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD [(n)-4182.8(160)-4317.1(n)]TJ -42.4773 -1.1128 TD [(3)-7821(n)-5106(320)-3836.5(n)-4935.3(n)-5504.3(0.496)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6823 Tc [(n8)4682.3(0)364.7(n)]TJ -42.4773 -1.1128 TD 0 Tc [(4)-7498.5(1000)-3829.7(n)-4935.3(n)-4935.3(n)]TJ /F6 1 Tf 30.919 0 TD (1.305)Tj /F5 1 Tf 6.9995 0 TD [(n)-3525.2(320)-4178(n)-4783.5(n)]TJ -37.9185 -1.1128 TD [(5)-7998(100)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.245)-4749.5(n)-3525.2(320)-4178(n)-4783.5(n)]TJ 0 -1.1065 TD [(6)-7998(320)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.481)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 3.9455 0 TD [(320)-4178(n)-4783.5(n)]TJ -42.0157 -1.1128 TD [(7)-7998(100)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.718)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 3.9455 0 TD [(320)-4215.9(80)-4317.6(n)]TJ -42.0157 -1.1128 TD [(8)-7998(320)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.162)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 3.9455 0 TD [(320)-4178(n)-4783.5(n)]TJ -42.0157 -1.1128 TD [(9)-7998(320)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.289)-4749.5(n)-3525.2(320)-4178(n)-4783.5(n)]TJ 0 -1.1065 TD [(10)-7498(100)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.093)-4749.5(n)-3525.2(320)-4178(n)-4783.5(n)]TJ 0 -1.1128 TD [(11)-7498(320)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.518)-4749.5(n)-4024.8(4)0(0)-4178.5(n)-4783.5(n)]TJ T* [(12)-7498(320)-3830.2(n)-4935.3(n)-4935.3(n)-5504.3(0.185)-4749.5(n)-4024.8(8)0(0)-4178.5(n)-4783.5(n)]TJ 0 -1.1065 TD [(13)-6998.5(1000)-3829.7(n)-4935.3(n)-4935.3(n)-5504.3(0.082)-4749.5(n)-3525.2(320)-4178(n)-4783.5(n)]TJ 0 -1.1128 TD [(14)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)-5504.3(0.450)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)259.2(4)4644.4(0)]TJ 6.7246 0 0 5.9768 540.8503 545.1022 Tm 0 Tc (a)Tj 8.9663 0 0 8.9663 59.811 531.1558 Tm [(15)-7321(n)-4935.3(n)-5106(320)-3836.5(n)-5504.3(0.358)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)259.2(4)4644.4(0)]TJ 6.7246 0 0 5.9768 540.8503 535.1243 Tm 0 Tc (a)Tj 8.9663 0 0 8.9663 59.811 521.1778 Tm [(16)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)-5504.3(0.507)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)259.2(4)4644.4(0)]TJ 6.7246 0 0 5.9768 540.8503 525.203 Tm 0 Tc (a)Tj 8.9663 0 0 8.9663 59.811 511.2566 Tm [(17)-7321(n)-4935.3(n)-5106(320)-3836.5(n)]TJ /F6 1 Tf 30.919 0 TD (0.879)Tj /F5 1 Tf 6.6517 0 TD (2)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)259.2(4)4644.4(0)]TJ 6.7246 0 0 5.9768 540.8503 515.225 Tm 0 Tc (a)Tj 8.9663 0 0 8.9663 59.811 501.2786 Tm [(18)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)]TJ /F6 1 Tf 30.919 0 TD (0.873)Tj /F5 1 Tf 6.6517 0 TD (2)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(19)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)-5504.3(0.684)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(20)-7321(n)-4935.3(n)-5106(320)-3836.5(n)-5504.3(0.724)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1065 TD 0 Tc [(21)-7321(n)-4935.3(n)-5106(320)-3836.5(n)-5504.3(0.366)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(22)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)-5504.3(0.784)-4401.7(3)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(23)-7321(n)-4935.3(n)-4606.5(1000)-3836.1(n)-5504.3(0.633)-4401.7(2)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1065 TD 0 Tc [(24)-7321(n)-4935.3(n)-5106(320)-3836.5(n)-5504.3(0.157)-4749.5(n)-3986.8(n)-4644.4(n)-4404.1(4)0(0)]TJ 0 -1.1128 TD [(25)-7321(n)]TJ /F12 1 Tf 12.7343 0 TD (>)Tj /F5 1 Tf .7651 0 TD (1000)Tj /F12 1 Tf 4.7359 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000)-3836.1(n)]TJ /F6 1 Tf 11.9124 0 TD (3.661)Tj /F5 1 Tf 6.6517 0 TD (3)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(26)-7321(n)]TJ /F12 1 Tf 12.7343 0 TD (>)Tj /F5 1 Tf .7651 0 TD [(1000)-3507.3(1000)-3836.1(n)]TJ /F6 1 Tf 17.4196 0 TD (2.951)Tj /F5 1 Tf 6.6517 0 TD (3)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc [(27)-7321(n)-5106(320)-3507.7(1000)-3836.1(n)]TJ /F6 1 Tf 30.919 0 TD (2.317)Tj /F5 1 Tf 6.6517 0 TD (3)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1065 TD 0 Tc [(28)-7321(n)-5106(100)-4007.3(320)-3836.5(n)]TJ /F6 1 Tf 30.919 0 TD (0.898)Tj /F5 1 Tf 6.6517 0 TD (3)Tj /F11 1 Tf .4995 0 TD ()Tj /F5 1 Tf 4.4071 0 TD 4.6444 Tc [(nn)240.3(4)4644.4(0)]TJ -42.4773 -1.1128 TD 0 Tc (29)Tj /F12 1 Tf 7.2271 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000)-3829.7(n)-4935.3(n)]TJ /F12 1 Tf 15.744 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000)-4405.1(0.670)-4749.5(n)-3525.2(320)-4178(n)-4783.5(n)]TJ -24.5139 -1.1128 TD (30)Tj /F12 1 Tf 7.2271 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000)-3829.7(n)-4935.3(n)]TJ /F12 1 Tf 15.744 0 TD (>)Tj /F5 1 Tf .7714 0 TD [(1000)-4405.1(0.430)-4401.7(2)]TJ /F11 1 Tf 13.5563 0 TD ()Tj /F5 1 Tf 3.9455 0 TD [(320)-4178(n)-4783.5(n)]TJ -42.0157 -1.1128 TD [(31)-6998.5(1000)-3829.7(n)-4935.3(n)-4606.5(1000)-4405.1(0.270)-4401.7(1)]TJ /F11 1 Tf 38.0702 0 TD ()Tj /F5 1 Tf 3.9455 0 TD [(320)-4215.9(40)-4317.6(n)]TJ 7.9702 0 0 7.9702 67.8047 353.6503 Tm [(n,)-330.3(Negative.)]TJ 0 -1.131 TD [(Shown)-326.5(in)-327.8(bold)-333.8(are)-325.7(ELISA)-327.2(equivalent/pos)9.7(itive)-333.8(results.)]TJ 5.9774 0 0 5.3127 67.8047 339.2503 Tm (a)Tj 7.9702 0 0 7.9702 70.7527 335.6786 Tm [(No)-329.9(further)-331.8(titration.)]TJ ET 59.811 135.836 490.167 .28348 re f 59.811 78.179 490.167 .22681 re f 59.811 116.844 490.167 .28342 re f BT /F7 1 Tf 8.9663 0 0 8.9663 130.7338 151.4834 Tm (Table)Tj /F5 1 Tf 3.0603 0 TD (4.)Tj /F7 1 Tf 1.2519 0 TD [(Agreement)-333.4(Among)-336.5(Commercial)-331(Assays)-336.5(and)-338(Virus)-333.1(Neutralization)-338.2(Test)]TJ 6.9489 -1.1128 TD [(for)-334.5(Toscana)-336.7(Virus)-339.4(IgG)-334.1(Detection)]TJ /F8 1 Tf -14.5237 -2.0423 TD [(IIFT)-337.1(\(Kappa)]TJ /F5 1 Tf 6.7246 0 0 5.9768 146.3244 127.1621 Tm (a)Tj /F8 1 Tf 8.9663 0 0 8.9663 149.6693 123.1937 Tm [(/%)-335.2(agreement\))-1823(ELISA)-337.6(\(Kappa/%)-331.2(agreement\))-1823(IB)-332.3(\(Kappa/%)-337.5(agreement\))-1823(VNT)-336(\(Kappa/%)-337.5(agreement\))]TJ /F5 1 Tf -10.0218 -2.0929 TD [(IIFT)-8244.1()-10881.2(0.111/50)-8956.2(0.235/60.8)-7877.4(0.179/53.3)]TJ 0 -1.1128 TD [(ELISA)-5186.5(0.111/50)-11630.8()-10255.3(0.175/62.5)-7877.4(0.248/81.7)]TJ T* [(IB)-7080.5(0.235/60.8)-8825.9(0.175/62.5)-10261.2()-9926.5(0.278/67.5)]TJ 5.9774 0 0 5.3127 67.8047 69.9023 Tm (a)Tj 7.9702 0 0 7.9702 70.7527 66.3307 Tm (Interpreted)Tj /F12 1 Tf 5.1641 0 TD (<)Tj /F5 1 Tf .7682 0 TD [(0)-246.9(a)0(s)-243.4(n)0(o)-252.7(agreemen)13(t)-247.1(and)-244.6(00.20)-244.6(as)-243.4(slight,)-249.5(0.210.4)14.6(0)-246.9(a)0(s)-250.6(fair,)-246.6(0.410.6)14.6(0)-246.9(a)0(s)-250.6(moderate,)-239(0.610.8)14.5(0)-246.9(a)0(s)-250.6(substantial)10.5(,)-247.9(and)-244.6(0.811)-244.6(as)-243.4(almost)]TJ -7.3052 -1.1239 TD [(perfect)-326.9(agreement.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(SERODIAGNOSIS)-341.6(OF)-331.2(TOSCANA)-340.3(VIRUS)-333.8(EXPOSURE)-28299.6(785)]TJ ET endstream endobj 73 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 75 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 76 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 74 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 62.022 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(titers)-360.5(were)-356.2(signicantly)-358.6(higher)-363.1(in)-354.7(VNT)-359.9(reactive)-358.1(than)-360.8(nonre-)]TJ 0 -1.2203 TD [(active)-281.6(samples,)-285.6(with)-280.9(TOSV)-279.2(antibody)-280.8(titers)-284.6(equal)-280.6(to)-281.4(or)-281.7(higher)]TJ 0 -1.2266 TD [(than)-215.4(1/320)-216(in)-215.6(all)-208.9(VNT)-214.5(reactive)-219(samples.)-216.1(Similar)-215.5(ndings)-218.1(were)]TJ 0 -1.2203 TD [(also)-317(noted)-313(for)-313.8(the)-319.9(majority)-311.1(of)-313.1(the)-319.9(SFSV/SFNV)-316.4(reactive)-313.9(sam-)]TJ T* [(ples)-398.1(as)-392.8(well.)-397.2(Thus,)-397.7(the)-395.8(IIFT)-391(can)-400.5(be)-390(used)-397.6(for)-396(screening)-401.5(pur-)]TJ 0 -1.2266 TD [(poses,)-211.9(but)-202.3(equivocal)-211.1(evaluations)-212(might)-205.4(require)-212.8(retesting)-210.1(and/)]TJ 0 -1.2203 TD [(or)-186.8(conrmation.)-183.7(A)-184.8(major)-188.9(advantage)-187.5(of)-180.3(the)-187.1(IIFT)-188.7(is)-181.9(the)-187.1(detection)]TJ T* [(of)-445.8(the)-452.7(antibody)-445.1(responses)-454.6(against)-448.4(four)-447.9(different)-448.1(SFV)-448.3(sero-)]TJ 0 -1.2266 TD [(types,)-617.4(enabling)-610.1(identication)-620.1(of)-610.2(probable)-611(cross-reactions.)]TJ 0 -1.2203 TD [(Nevertheless,)-374.4(IIFT)-365.7(is)-365.3(a)-366.2(labor-intensive)-369(method)-367.5(that)-370.6(requires)]TJ T* [(the)-351.5(individual)-353.9(examination)-357.2(of)-351(all)-354.3(samples)-352.3(in)-348.4(the)-357.8(uorescent)]TJ T* [(microscope,)-295.9(and)-290.4(the)-294.6(interpretation)-298.3(can)-293(vary)-289.9(according)-294.1(to)-294.1(the)]TJ 0 -1.2266 TD (microscopist.)Tj 1.1128 -1.2203 TD [(In)-650.4(TOSV)-646(ELISA,)-649.5(equivocal)-653.7(and)-650.8(positive)-652.2(results)-653.5(were)]TJ -1.1128 -1.2203 TD [(equally)-320.2(distributed)-318.9(in)-323.1(VNT-reactive)-320.1(samples)-320.6(and)-322(in)-316.7(samples)]TJ 0 -1.2266 TD [(reactive)-320.2(via)-319.9(TOSV)-317.2(IIFT)-315.2(or)-319.6(IB)-321.3(\(data)-319.1(not)-316.5(shown\).)-319.4(Thus,)-321.8(equiv-)]TJ 0 -1.2203 TD [(ocal)-466.7(results)-463.8(from)-463.1(this)-470.3(assay)-461.3(strongly)-463.6(imply)-465.7(reactivity.)-464.4(The)]TJ T* [(TOSV)-235(IB)-226.4(assay)-233.7(displayed)-228.2(reactivity)-233.9(in)-234.5(all)-227.9(SFNV)-233.3(VNT-positive)]TJ 0 -1.2266 TD [(samples)-339.6(and)-334.7(in)-329.4(the)-338.9(majority)-336.4(of)-332(the)-338.9(SFNV)-334.5(and)-334.7(SFNV)]TJ /F11 1 Tf 23.2746 0 TD ()Tj /F5 1 Tf .7714 0 TD (TOSV)Tj -24.046 -1.2203 TD [(IIFT)-454.3(reactive)-459.3(samples,)-456.3(which)-453.8(suggests)-457.1(cross-reactions)-465.7(with)]TJ T* [(SFNV.)-331.1(However,)-331(this)-331.2(assay)-328.5(provided)-324.8(negative)-334.3(results)-331.1(in)-329.4(the)]TJ T* [(majority)-254.2(of)-249.8(the)-256.7(IIFT)-245.6(or)-256.4(ELISA)-248.3(equivocal)-255.3(samples)-251.1(and)-252.5(positive)]TJ 0 -1.2266 TD [(results)-413.2(in)-411.6(the)-414.7(majority)-412.3(of)-414.2(the)-414.7(TOSV)-412(VNT-positive)-411.9(samples.)]TJ 0 -1.2203 TD [(Thus,)-302.8(IB)-296(can)-299.4(be)-301.5(employed)-297(as)-304.3(a)-296.7(conrmatory)-299.1(assay)-303.2(for)-301.1(TOSV)]TJ T* [(exposure)-395.2(for)-389.6(samples)-390.2(reactive)-396.1(in)-392.6(TOSV)-386.7(IIFT)-391(or)-389.2(ELISA.)-390.3(The)]TJ 0 -1.2266 TD [(ELISA)-412.7(format)-412.5(enables)-410.3(rapid)-412.8(testing)-411.8(and)-410.6(interpretation)-418.4(in)-411.6(a)]TJ 0 -1.2203 TD [(high)-299.3(number)-304.5(of)-300.4(samples)-301.7(and)-303.1(can)-299.4(be)-301.5(easily)-296.7(automated.)-304.7(It)-299.8(has)]TJ T* [(been)-317.4(previously)-323.1(reported)-318.6(that)-320(for)-320.1(TOSV,)-320.1(the)-319.9(performance)-321.7(of)]TJ 0 -1.2266 TD [(whole)-302.1(virus)-292.2(and)-296.8(recombinant)-305.8(nucleocapsid)-296.4(ELISAs)-300.2(correlate)]TJ 0 -1.2203 TD [(well)-451.2(\(Valassina)-451.2(et)-449.3(al.)-448.6(1998\).)-450.4(However,)-451.1(the)-452.7(relatively)-452.5(lower)]TJ T* [(sensitivity)-319.8(observed)-316.2(for)-307.4(the)-319.9(ELISA,)-308.1(as)-317(compared)-313.9(to)-313.1(IIFT)-308.8(and)]TJ 0 -1.2266 TD [(VNT,)-255.3(suggests)-261.1(that)-256.8(the)-256.7(seroprevalence)-259.5(rates)-254.8(might)-262.3(have)-256.5(been)]TJ 0 -1.2203 TD [(underestimated)-279.6(in)-266.2(the)-275.6(previous)-270.9(studies)-276.4(where)-271.1(this)-274.3(assay)-271.6(was)]TJ T* [(employed)-214.8(for)-218.9(surveillance)-219(\(Echevarria)-219.4(et)-215.3(al.)-214.6(2003,)-209.6(Valassina)-216.8(et)]TJ T* [(al.)-461.2(2003,)-456.2(Terrosi)-460.8(et)-461.9(al.)-461.2(2009\).)-456.7(The)-461.5(IB)-460.4(assay)-455(requires)-467.1(longer)]TJ 0 -1.2266 TD [(hands-on)-371.3(time)-368.2(than)-373.5(ELISA)-368.4(or)-370.2(IIFT)-365.7(but)-366.6(provides)-373.7(data)-369.2(about)]TJ 0 -1.2203 TD [(Hantavirus)-193.9(exposure)-199.1(\(serotypes)-196(Hantaan,)-192(Puumala,)-190.5(Dobrava,)]TJ T* [(Seoul\))-284.7(in)-278.8(the)-282(same)-282.8(strip)-285.6(as)-279(well.)]TJ 1.1128 -1.2266 TD [(An)-327.3(interesting)-330.8(nding)-330.6(is)-327.3(that)-326.3(VNT,)-324.9(which)-333.7(is)-321(generally)-329.1(re-)]TJ -1.1128 -1.2203 TD [(garded)-434.2(as)-430.8(the)-433.7(gold-standard)-436.1(assay)-429.7(for)-433.9(specicity,)-436.3(has)-434.2(pro-)]TJ T* [(vided)-307.4(conrmation)-313.6(only)-311.3(in)-304.1(a)-309.3(portion)-312.2(of)-306.7(the)-307.3(samples)-314.3(reactive)]TJ 0 -1.2266 TD [(for)-231.6(TOSV)-228.6(immunoglobulins)-236.8(via)-231.4(any)-228.6(assay)-233.7(and)-227.2(observed)-234(to)-230.9(be)]TJ 0 -1.2203 TD [(relatively)-357.7(insensitive.)-359(Moreover,)-350.6(the)-357.8(agreement)-353.5(of)-351(VNT)-353.6(and)]TJ T* [(the)-332.5(commercial)-338.8(assays)-336.2(was)-331.2(interpreted)-335.8(as)-335.9(slight.)-335.7(It)-331.4(has)-333(been)]TJ T* [(known)-553(that)-560.3(phleboviral)-554.5(neutralization)-559(is)-554.9(a)-549.6(complex)-556.7(phe-)]TJ 0 -1.2266 TD [(nomenon)-202.9(involving)-196.8(a)-201.8(number)-197(antigenic)-200.8(epitopes)-200.3(and)-201.9(even)-199.9(the)]TJ 0 -1.2203 TD [(majority)-368(of)-363.6(the)-364.2(exposed)-370.8(persons)-364.8(develop)-365.3(antibodies)-369.6(against)]TJ T* [(linear)-421.6(epitopes)-421.6(of)-420.6(N)-417.3(protein,)-426(the)-421.1(immune)-420.6(response)-421.6(against)]TJ 0 -1.2267 TD [(viral)-235.6(glycoproteins,)-233.1(which)-232.5(affects)-235.4(virus)-235.3(neutralization)]TJ /F8 1 Tf 23.4454 0 TD [(in)-233.9(vitro)]TJ /F5 1 Tf 2.9718 0 TD (,)Tj -26.4171 -1.2203 TD [(have)-237.5(been)-241.5(shown)-233.8(to)-237.2(display)-238(considerable)-242.6(variation)-235.5(\(Besselaar)]TJ T* [(and)-499.1(Blackburn)-493.8(1991,)-500.5(Di)-491.8(Bonito)-502.8(et)-493.6(al.)-499.1(2002\).)-494.6(Patients)-503.1(with)]TJ 0 -1.2266 TD [(TOSV-induced)-280.5(neurological)-283.9(disease)-280.4(have)-275.4(also)-279(been)-279.5(observed)]TJ 0 -1.2203 TD [(to)-218.2(develop)-219.9(a)-214.5(differential)-227.1(antibody)-217.5(response)-219.3(against)-220.8(denatured)]TJ T* [(viral)-349.5(proteins)-354.9(\(Di)-353.2(Bonito)-351.1(et)-348.1(al.)-353.7(2002\).)-349.2(The)-347.7(presence)-359.8(of)-344.7(TOSV)]TJ 0 -1.2266 TD [(glycoprotein-precititating)-585(antibodies)-578.3(were)-577.5(associated)-579.7(with)]TJ 0 -1.2203 TD [(higher)-287.2(neutralizing)-288.8(antibody)-287.1(titers)-290.9(in)-285.1(acute)-285(and)-290.4(convelescent)]TJ T* [(sera)-248(\()-82.7(Magurano)-250.7(and)-246.2(Nicoletti)-253.7(1999\).)-241.7(In)-252.1(addition,)-249.8(neutralizing)]TJ T* [(epitopes)-250.9(may)-241.8(not)-246.9(necessarily)-250.7(be)-244.6(detected)-246.2(in)-247.2(diagnostic)-248.9(assays)]TJ 0 -1.2266 TD [(and)-189.3(may)-184.9(depend)-187.6(on)-189.5(tertiary)-186.7(structures)-190.2(that)-187.2(may)-191.2(be)-181.4(lost)-191.5(during)]TJ 0 -1.2203 TD [(assay)-278(development)-278.1(\()-89(Magurano)-276(and)-277.8(Nicoletti)-279(1999,)-279.2(Di)-276.8(Bonito)]TJ T* [(et)-556.8(al.)-556.1(2002\).)-557.9(These)-557.6(variations)-559.2(may)-557.9(account)-562.5(for)-554(the)-560.2(slight)]TJ 0 -1.2267 TD [(agreement)-530.5(observed)-524.9(among)-526.1(commercial)-522.1(diagnostic)-533.4(assays)]TJ 27.9978 74.5598 TD [(and)-252.5(VNT.)-255.3(A)-254.3(similar)-250(phenomenon)-258.1(has)-257.1(also)-253.7(been)-247.9(described)-255.3(for)]TJ 0 -1.2203 TD [(mosquito-borne)-202.9(aviviruses)-199(West)-203(Nile)-196.6(virus)-197.3(and)-195.6(Yellow)-198.9(fever)]TJ 0 -1.2266 TD [(virus,)-421.6(where)-416.5(correlation)-414.9(of)-414.2(ratio/titers)-421(of)-414.2(ELISA)-419(or)-414.5(IIFT)-410(to)]TJ 0 -1.2203 TD [(VNT)-214.5(has)-206.5(observed)-208.8(to)-211.9(be)-206.6(low)-203.9(\(Niedrig)-211.5(et)-209(al.)-208.3(1999,)-203.3(Niedrig)-211.1(et)-209(al.)]TJ T* [(2007\).)-880.3(Nevertheless,)-880.2(VNTs)-873.4(are)-879(still)-872.3(essential)-879.1(for)-876.5(ser-)]TJ 0 -1.2266 TD [(oepidemiological)-290.2(studies)-282.8(for)-282.2(conrming)-283.6(the)-282(presence)-283.9(of)-281.4(neu-)]TJ 0 -1.2203 TD [(tralizing)-372.7(antibodies.)-372.5(It)-369.3(also)-373.9(remains)-366.3(to)-370(be)-371(veried)-371.2(if)-370.7(surface)]TJ T* [(glycoprotein)-405.9(variants)-407.5(of)-395.3(TOSV)-405.7(also)-399.2(co-circulate)-402.1(in)-405.3(endemic)]TJ 0 -1.2266 TD [(areas)-500.4(and)-499.1(are)-499.6(involved)-504.5(in)-493.8(human)-504.7(immune)-496.5(response)-503.8(with)]TJ 0 -1.2203 TD [(probable)-320.1(consequences)-326(in)-323.1(diagnostic)-318.4(serology.)-319.9(Nevertheless,)]TJ T* [(it)-535.1(is)-529.6(likely)-531.5(that)-535(TOSV)-532.1(diagnostic)-533.4(assays)-532.2(will)-530.7(signicantly)]TJ T* [(benet)-295.6(from)-292.4(inclusion)-294(of)-287.8(viral)-292.6(glycoprotein)-298.4(antigens)-287.8(in)-291.4(addi-)]TJ 0 -1.2266 TD [(tion)-288.4(to)-281.5(nucleocapsid.)]TJ 1.1128 -1.2203 TD [(In)-486(conclusion,)-491.4(commercially)-485.8(available)-488.4(diagnostic)-489.1(immu-)]TJ -1.1128 -1.2203 TD [(noassays)-203.2(displayed)-202.9(slight-to-fair)-208.4(agreement)-201.8(as)-196.8(determined)-201(for)]TJ 0 -1.2266 TD [(IgG)-435.2(in)-436.9(sera)-437.7(from)-437.8(asymptomatic)-437.7(blood)-433.8(donors)-437.6(from)-437.8(an)-432.9(en-)]TJ 0 -1.2203 TD [(demic)-325.7(region.)-327.4(The)-328.8(results)-331.1(could)-326.1(only)-323.9(be)-326.8(conrmed)-325.8(via)-326.3(virus)]TJ T* [(neutralization)-287.1(in)-285.1(a)-277.7(portion)-286.9(of)-281.5(the)-282(samples,)-285.6(and)-277.8(overall)-282.6(agree-)]TJ 0 -1.2266 TD [(ment)-298.5(between)-300.5(the)-294.6(commercial)-300.8(assays)-291.9(and)-296.7(VNT)-296.7(is)-295.7(slight.)-297.8(The)]TJ 0 -1.2203 TD [(IIFT)-429(could)-427.3(be)-427.9(used)-422.9(for)-427.6(screening)-433.1(purposes,)-430.3(and)-423.2(for)-427.6(conr-)]TJ T* [(mation)-291.8(of)-287.8(TOSV)-291.9(exposure,)-290.6(commercial)-288.2(assays)-291.9(such)-289.9(as)-285.4(IB)-289.6(can)]TJ T* [(be)-282.5(performed)-284.6(in)-278.8(addition)-284.8(to)-281.4(VNT.)]TJ /F3 1 Tf 0 -2.6809 TD (Acknowledgments)Tj /F5 1 Tf 1.1128 -1.8336 TD [(This)-346.3(work)-338.3(was)-343.9(partially)-339(funded)-346.2(by)-343.9(Turkish)-340.2(Red)-342.2(Crescent)]TJ -1.1128 -1.2203 TD [(Society)-211.2(and)-208.2(Hacettepe)-215.7(University)-215.4(Research)-210.6(Fund)-208.2(\(Project)-212.2(NO:)]TJ 0 -1.2266 TD [(08)-422.7(O)-420.4(101)-422.2(001\))-422.6(and)-423.2(by)-419.8(BMBF)-420.2(grant)-425.8(01KI0710)-419.3()80.3(Research)-427.4(on)]TJ 0 -1.2203 TD [(Zoonotic)-215.2(Infectious)-216.9(Diseases)-212.4(program;)-212.3(Emerging)-212.9(Arthropod-)]TJ T* [(Borne-Viral)-222.7(Infections)-219(in)-215.6(Germany:)-215.8(Pathogenesis,)-220.2(Diagnostics)]TJ T* [(and)-284.1(Surveillance.)76.2()]TJ /F3 1 Tf 0 -2.6683 TD [(Disclosure)-336.7(Statement)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Nadine)-597.3(Litzba)-592.2(received)-601.3(funding)-594.9(from)-595.9(the)-591.8(Euroimmun)]TJ -1.1128 -1.2203 TD [(Medizinische)-474.3(Labordiagnostika)-466.2(AG,)-471(Germany.)-462.4(All)-470(authors)]TJ 0 -1.2266 TD [(declare)-284(that)-282(no)-284.4(further)-285.2(competing)-284.6(nancial)-280.7(interests)-282.9(exist.)]TJ /F3 1 Tf 0 -2.6683 TD (References)Tj /F5 1 Tf 8.4682 0 0 8.4682 313.0582 298.1479 Tm [(Besselaar,)-271.2(TG,)-260.5(Blackburn,)-261.6(NK.)-265.3(Topological)-264.1(mapping)-265.1(of)-261.7(antigenic)]TJ .9707 -1.2318 TD [(sites)-520.5(on)-520.5(the)-519.2(Rift)-517.9(Valley)-513.9(fever)-519.8(virus)-521.3(envelope)-519.1(glycoproteins)]TJ 0 -1.2385 TD [(using)-337.6(monoclonal)-342.1(antibodies.)-334.5(Arch)-339.9(Virol)-338(1991;)-334.2(121:111124.)]TJ -.9707 -1.2318 TD [(Calisher,)-376.8(CH,)-362.3(Beaty,)-370.2(BJ,)-370.5(Chandler,)-366.5(LJ.)-370.5(Arboviruses.)-372.9(In:)-364.7(Lenette,)]TJ .9707 -1.2385 TD [(EH,)-319.1(Smith,)-313.2(TF,)-314.6(eds.)]TJ /F8 1 Tf 8.8974 0 TD [(Laboratory)-323(Diagnosis)-312.2(of)-317.3(Viral)-316.7(Infections)]TJ /F5 1 Tf 16.3152 0 TD [(,)-312.4(3rd)]TJ -25.2126 -1.2318 TD [(edition.)-450.2(Revised)-451.5(and)-439.6(Expanded.)-450(New)-447.8(York:)-444.6(Marcel)-446.5(Dekker,)]TJ 0 -1.2385 TD [(1999:305332)-7.5(.)]TJ -.9707 -1.2385 TD [(Charel,)-504.8(RN,)-498.1(Gallian,)-504.9(P,)-496(Navarro-Mari,)-505.6(JM,)-499.4(Nicoletti,)-500.6(L,)-498.4(et)-502.1(al.)]TJ .9707 -1.2318 TD [(Emerg)-8.2(ence)-264.3(of)-268.4(Toscana)-272.8(virus)-266.9(in)-271.7(Europe.)-268.2(Emerg)-269.3(Infect)-270.8(Dis)-267(2005;)]TJ 0 -1.2385 TD [(11:16571663)-7.5(.)]TJ -.9707 -1.2318 TD [(Ciufolini,)-308.6(MG,)-295.8(Fiorentini,)-308.6(C,)-300.6(Di)-294.7(Bonito,)-303.4(P,)-301.8(Mochi,)-302.6(S,)-294.5(et)-301.3(al.)-301.3(Detec-)]TJ .9707 -1.2385 TD [(tion)-218.8(of)-221.6(Toscana)-219.3(virus-specic)-223.6(immunoglobulins)-221.1(G)-217.4(and)-211.9(M)-221.2(b)0(y)-214.9(a)0(n)]TJ 0 -1.2318 TD [(enzyme-linked)-447.6(immunosorbent)-444.9(assay)-441.2(based)-439.2(on)-440.2(recombinant)]TJ 0 -1.2385 TD [(viral)-287.3(nucleoprotein.)-290.4(J)-280.5(Clin)-280.3(Microbiol)-283(1999;)-280.6(37:20102012.)]TJ -.9707 -1.2318 TD [(Clarke,)-504.7(DH,)-501.2(Cassals,)-503.1(J.)-499.2(Techniques)-506.7(for)-499.3(hemagglutination)-504.2(and)]TJ .9707 -1.2385 TD [(hema)-8.5(gglutination-inhibition)-745.6(with)-736.9(arthropod-bo)-13.4(rne)-737.4(viruses.)]TJ 0 -1.2318 TD [(Am)-336.7(J)-334.1(Trop)-334(Med)-340.9(Hyg)-330.2(1958;)-334.2(7:561573.)]TJ -.9707 -1.2385 TD [(Cusi,)-269.2(MG,)-262.3(Valensin,)-266.9(PE,)-260.2(Donati,)-265.4(M,)-265.8(Valassina,)-265.8(M.)-265.8(Neutralization)]TJ .9707 -1.2318 TD [(of)-469.3(Toscana)-467(virus)-474.4(is)-461.2(partially)-469.2(mediated)-470.6(by)-462.6(antibodies)-470.7(to)-469.3(the)]TJ 0 -1.2385 TD [(nucleocapsid)-342.5(protein.)-337.1(J)-334.1(Med)-340.9(Virol)-331.3(2001;)-334.2(63:7275.)]TJ -.9707 -1.2318 TD [(Davies,)-475.3(FG,)-466.5(Jacobsen,)-467.7(P,)-469.2(Sylla,)-461.3(D.)-466.2(Laboratory)-473.8(manual)-468.3(on)-467(Rift)]TJ .9707 -1.2385 TD [(Valley)-259.5(fever:)-256.4(isolation)-261.8(and)-252.1(identication)-260.4(technics.)-261.9(In:)-257.6(Report)-258.6(of)]TJ 0 -1.2318 TD [(FAO/WHO)-273.5(group)-268.3(on)-266.1(emergency)-270.9(prep)-9.6(aredness)-268.2(for)-271.7(Rift)-263.5(Valley)]TJ 0 -1.2385 TD [(Fever)-336.7(control)-342(in)-332(West)-338(Africa)-337.8(\(WHO-VPH/88.77\).)-339.1(1988:1134.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 62.022 749.6502 Tm (786)Tj 46.1193 0 TD (ERGU)Tj 2.3648 .2023 TD ()Tj .5185 -.2023 TD [(NAY)-332.3(ET)-338.7(AL.)]TJ ET endstream endobj 77 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 79 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 80 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 78 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.4682 0 0 8.4682 59.7543 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(Di)-348.2(Bonito,)-350.2(P,)-348.7(Bosco,)-350.9(S,)-348(Mochi,)-349.5(S,)-348(Accardi,)-346.2(L,)-351.1(et)-348.1(al.)-348.1(Human)-346.9(anti-)]TJ .9707 -1.2318 TD [(body)-442.3(response)-445.8(to)-442.5(Toscana)-446.9(virus)-440.9(glycoproteins)-452.6(expressed)-445.4(by)]TJ 0 -1.2385 TD [(recombinant)-339.6(baculovirus.)-339.8(J)-334.1(Med)-334.2(Virol)-338(2002;)-334.2(68:615619.)]TJ -.9707 -1.2318 TD [(Dionisio,)-391.9(D,)-392.6(Esperti,)-389.9(F,)-389.7(Vivarelli,)-391.5(A,)-385.9(Valassina,)-393(M.)-386.3(Epidemiolo-)]TJ .9707 -1.2385 TD [(gical,)-443.9(clinical)-438.1(and)-446.3(laboratory)-442(aspects)-443.1(of)-442.5(Sandy)-437.3(Fever.)-441.5(Curr)]TJ 0 -1.2318 TD [(Opin)-337.1(Infect)-337.7(Dis)-333.9(2003;)-334.2(16:383388.)]TJ -.9707 -1.2385 TD [(Echevarria,)-217.7(JM,)-211.6(de)-213.4(Orf,)-210.2(F,)-215.6(Guisasola,)-215.3(ME,)-210.8(Sanchez-Seco,)-219.6(MP,)-208.4(et)-214.2(al.)]TJ .9707 -1.2318 TD [(Acute)-436.1(meningitis)-434.6(due)-430.5(to)-435.8(Toscana)-433.5(virus)-427.5(infection)-441.8(among)-427.9(pa-)]TJ 0 -1.2385 TD [(tients)-457.6(from)-461.2(both)-449.9(the)-459(Spanish)-455.8(Mediterranean)-460.4(region)-461.4(and)-452.9(the)]TJ 0 -1.2318 TD [(region)-340.9(of)-335.4(Madrid.)-335.4(J)-334.1(Clin)-333.8(Virol)-338(2003;)-334.2(26:7984.)]TJ -.9707 -1.2385 TD [(Eitrem,)-631(R,)-630.5(Niklasson,)-631.1(B,)-625.5(Weiland,)-629.9(O.)-629.3(Sandy)-624.7(virus)-628.4(among)]TJ .9707 -1.2318 TD [(Swedish)-343(tourists.)-336.9(J)-334.1(Infect)-337.7(Dis)-333.9(1991b;)-337.9(23:451457.)]TJ -.9707 -1.2385 TD [(Eitrem,)-503.8(R,)-496.6(Stylianou,)-502(M,)-493.4(Niklasson,)-503.9(B.)-498.3(High)-497.8(prevalence)-501.3(rates)]TJ .9707 -1.2318 TD [(of)-469.3(antibody)-474.5(to)-469.3(three)-469.6(sandy)-474.3(fever)-466.2(viruses)-474.1(\(Sicilian,)-472.6(Naples,)]TJ 0 -1.2385 TD [(and)-814.5(Toscana\))-814.5(among)-809.5(Cypriots.)-812.4(Epidemiol)-814.5(Infect)-813.1(1991a;)]TJ 0 -1.2318 TD (107:685691.)Tj -.9707 -1.2385 TD (Ergu)Tj 1.667 .0134 TD ()Tj .4686 -.0134 TD [(nay,)-435.7(K,)-424.5(Saygan,)-437(MB,)-425(Aydog)]TJ 12.2916 0 TD [()-119.9(an,)-432(S,)-428.4(Lo,)-432.7(MM,)-426.7(et)-435.1(al.)-428.5(Sandy)]TJ -13.4565 -1.2318 TD [(Fever)-524.1(virus)-528(activity)-525.6(in)-519.4(Central/Northern)-535.2(Anatolia,)-522.1(Turkey:)]TJ 0 -1.2385 TD [(rst)-395.3(report)-399(of)-395.6(Toscana)-400(virus)-394.1(infections.)-398.4(Clin)-400.8(Microbiol)-396.8(Infect)]TJ T* [(2010)-483.8([Epub)-482.6(ahead)-482.5(of)-482.7(print];)-488.5(DOI:)-483.7(10.1111/j.14690691.2010.)]TJ 0 -1.2318 TD (03346.x.)Tj -.9707 -1.2385 TD [(Hemmersbach-Miller,)-500.7(M,)-493.4(Parola,)-491.6(P,)-489.3(Charrel,)-494.7(RN,)-491.4(Durand,)-496.9(JP,)]TJ .9707 -1.2318 TD [(et)-368.2(al.)-368.2(Sandy)-363.6(fever)-372.5(due)-363.5(to)-368.8(Toscana)-366.5(virus:)-365(an)-367.4(emerging)-366(infec-)]TJ 0 -1.2385 TD [(tion)-339.3(in)-332(southern)-342(France.)-337.4(Eur)-332.7(J)-334.1(Intern)-340.6(Med)-334.2(2004;)-334.2(15:316317.)]TJ -.9707 -1.2318 TD [(Ilstrup,)-308.3(DM.)-299.2(Statistical)-303.5(methods)-305.9(in)-298.5(microbiology.)-304.5(Clin)-307(Microbiol)]TJ .9707 -1.2385 TD [(Rev)-339.2(1990;)-334.2(3:219226.)]TJ -.9707 -1.2318 TD [(Landis,)-334.6(JR,)-328.6(Koch,)-327.3(GG.)-332.2(The)-324.3(measurement)-337.7(of)-328.7(observer)-333.6(agreement)]TJ .9707 -1.2385 TD [(for)-338.7(categorical)-337.2(data.)-334.6(Biometrics)-337.5(1977;)-334.2(33:159174.)]TJ -.9707 -1.2318 TD [(Magurano,)-405.3(F,)-403.1(Nicoletti,)-406.9(L.)-397.9(Humoral)-401.5(response)-405.6(in)-405.6(Toscana)-400(virus)]TJ .9707 -1.2385 TD [(acute)-324.4(neurologic)-329.9(disease)-321.6(investigated)-329.2(by)-322(viral-protein-specic)]TJ 0 -1.2318 TD [(immunoassays.)-343(Clin)-333.8(Diagn)-337.7(Lab)-332.4(Immunol)-335.2(1999;)-334.2(6:5560.)]TJ -.9707 -1.2385 TD [(Mertz,)-599.2(GJ.)-602.8(Bunyaviridae:)-596.4(Bunyaviruses,)-603.2(Phleboviruses,)-604.7(Nair-)]TJ .9707 -1.2318 TD [(oviruses)-542.3(and)-540(Hantaviruses.)-540.9(In:)-538.8(Richman,)-540.1(DD,)-539.8(Whitley,)-538.6(RJ,)]TJ 0 -1.2385 TD [(Hayden,)-623.8(FG,)-613.8(eds.)]TJ /F8 1 Tf 8.9241 0 TD [(Clinical)-621.5(Virology)]TJ /F5 1 Tf 7.2839 0 TD [(.)-620.3(New)-615.2(York:)-618.7(Churchill-)]TJ -16.2081 -1.2318 TD [(Livingstone,)-343.2(1997:943971.)]TJ -.9707 -1.2385 TD [(Nicoletti,)-427(L,)-411.3(Ciufolini,)-422.4(MG,)-416.3(Verani,)-421.1(P.)-415.6(Sandy)-417.2(fever)-419.4(viruses)-420.6(in)]TJ .9707 -1.2318 TD [(Italy.)-339.5(Arch)-333.2(Virol)-338(1996;)-334.2(11:4147.)]TJ -.9707 -1.2385 TD [(Niedrig,)-460.9(M,)-459.9(Lademann,)-457.7(M,)-453.2(Emmerich,)-461.6(P,)-455.8(Lafrenz,)-462.8(M.)-453.2(Assess-)]TJ .9707 -1.2318 TD [(ment)-440.9(of)-442.5(IgG)-437.1(antibodies)-443.9(directed)-441.2(against)-438.7(Yellow)-444.8(Fever)-437.1(virus)]TJ 0 -1.2385 TD [(after)-352.9(vaccination)-357.5(with)-348.6(17D)-352.3(by)-348.8(different)-353.2(assays:)-351(neutralization)]TJ 0 -1.2318 TD [(test,)-511.6(haemagglutination)-506.3(inhibition)-511.7(test,)-504.9(immunouorescence)]TJ 0 -1.2385 TD [(assay)-340.8(and)-332.4(ELISA.)-333.4(Trop)-340.7(Med)-334.2(Int)-332.9(Health)-335.5(1999;)-334.2(4:867871.)]TJ 28.6805 50.646 TD [(Niedrig,)-400.7(M,)-399.7(Sonnenberg,)-399.3(K,)-397.7(Steinhagen)-13.4(,)-392.7(K)0(,)-397.7(Paweska,)-400.3(JT.)-404(Com-)]TJ .9707 -1.2318 TD [(parison)-293.7(of)-295.2(ELISA)-295.5(and)-299(immunoassays)-298.4(for)-291.8(measurement)-297.6(of)-295.2(IgG)]TJ 0 -1.2385 TD [(and)-379.3(IgM)-380.6(antibody)-380.8(to)-375.5(West)-384.9(Nile)-377.4(virus)-380.7(in)-378.8(human)-382.7(sera)-380(against)]TJ 0 -1.2318 TD [(virus)-333.8(neutralisation.)-343.9(J)-334.1(Virol)-338(Methods)-337.7(2007;)-334.2(139:103105.)]TJ -.9707 -1.2385 TD [(Sanbonmatsu-Gamez,)-250.3(S,)-247.6(Perez-Ruiz,)-249.5(M,)-239(Collao,)-252.1(X,)-242.2(Sanchez-Seco,)]TJ .9707 -1.2318 TD [(MP,)-523(et)-522.2(al.)-522.2(Toscana)-520.5(virus)-528(in)-519.4(Spain.)-524.3(Emerg)-523.7(Infect)-525.2(Dis)-521.4(2005;)]TJ 0 -1.2385 TD (11:17011707.)Tj -.9707 -1.2318 TD [(Schwarz,)-374.7(TF,)-381.5(Jager,)-375(G,)-375.8(Gilch,)-378.1(S,)-374.8(Pauli,)-380.8(C.)-374.3(Serosurvey)-378.8(and)-379.3(labo-)]TJ .9707 -1.2385 TD [(ratory)-307.6(diagnosis)-315.8(of)-308.6(imported)-309.4(sandy)-313.6(virus,)-311.4(serotype)-312.1(Toscana,)]TJ 0 -1.2318 TD [(infection)-341.4(in)-332(Germany.)-337.8(Epidemiol)-339.1(Infect)-337.7(1995;)-327.5(114:501510.)]TJ -.9707 -1.2385 TD [(Schwarz,)-334.5(TF,)-334.6(Gilch,)-337.9(S,)-341.3(Pauli,)-333.9(C,)-334.1(Jager,)-341.5(G.)-329(Immunoblot)-346.2(detection)]TJ .9707 -1.2318 TD [(of)-335.4(antibodies)-336.8(to)-335.4(Toscana)-339.8(virus.)-331.5(J)-334.1(Med)-334.2(Virol)-338(1996;)-334.2(49:8386.)]TJ -.9707 -1.2385 TD [(Schwarz,)-528.7(TF,)-528.8(Gilch,)-532.1(S,)-528.8(Schatzl,)-527.8(HM.)-528.3(A)-528.8(recombinant)-533.7(Toscana)]TJ .9707 -1.2318 TD [(virus)-400.8(nucleoprotein)-413.2(in)-398.9(a)-403.8(diagnostic)-401.3(immunoblot)-404.9(system.)-403.2(Res)]TJ 0 -1.2385 TD [(Virol)-331.3(1998;)-334.2(149:413418.)]TJ -.9707 -1.2318 TD [(Soldateschi,)-445(D,)-446.2(dal)-442.7(Maso,)-449(GM,)-443.1(Valassina,)-446.5(M,)-446.5(Santini,)-444.4(L,)-444.8(et)-441.8(al.)]TJ .9707 -1.2385 TD [(Laboratory)-460.5(diagnosis)-456.4(of)-455.9(Toscana)-460.3(virus)-461(infection)-461.9(by)-455.9(enzyme)]TJ 0 -1.2318 TD [(immunoassay)-526.9(with)-522.6(recombinant)-527(viral)-521.6(nucleoprotein.)-531.4(J)-521.5(Clin)]TJ 0 -1.2385 TD [(Microbiol)-336.6(1999;)-334.2(37:649652.)]TJ -.9707 -1.2385 TD [(Terrosi,)-258.4(C,)-260.5(Olivieri,)-259.4(R,)-262.3(Bianco,)-256.1(C,)-260.5(Cellesi,)-261.4(C,)-253.8(et)-261.1(al.)-261.1(Age-dependent)]TJ .9707 -1.2318 TD [(seroprevalence)-411.9(of)-402.3(Toscana)-406.7(virus)-407.4(in)-398.9(central)-409.2(Italy)-402(and)-406.1(correla-)]TJ 0 -1.2385 TD [(tion)-546.8(with)-556.1(the)-546(clinical)-551.9(prole.)-553.5(Clin)-548(Vaccine)-557(Immunol)-549.4(2009;)]TJ 0 -1.2318 TD (16:12511252.)Tj -.9707 -1.2385 TD [(Valassina,)-446.5(M,)-439.8(Soldateschi,)-451.7(D,)-446.2(dal)-442.7(Maso,)-442.3(GM,)-449.7(Santini,)-444.4(L,)-444.8(et)-441.8(al.)]TJ .9707 -1.2318 TD [(Diagnostic)-362.5(potential)-357.8(of)-355.5(Toscana)-359.9(virus)-360.6(N)-356.3(protein)-359.5(expressed)-365.1(in)]TJ /F8 1 Tf 0 -1.2385 TD [(Echerichia)-335.9(coli)]TJ /F5 1 Tf 5.8847 0 TD [(.)-332.4(J)-334.1(Clin)-333.8(Microbiol)-343.3(1998;)-327.5(36:31703172)-7.5(.)]TJ -6.8555 -1.2318 TD [(Va)19.6(l)13.2(a)0(s)18.9(s)0(i)14.1(n)0(a)20.9(,)-593.5(M)13.1(,)-593.5(Va)19.6(le)19.3(nt)17(in)16.2(i)13.2(,)-593.5(M,)-580.4(Pu)14.4(gl)22.9(ie)19.3(se)13.7(,)-586.8(A)0(,)-586.8(V)0(a)19.6(l)13.2(en)15.7(si)20.8(n,)-583.9(PE)18.7(,)-593.5(e)0(t)-582.4(a)0(l)17.8(.)]TJ .9707 -1.2385 TD [(Se)17.3(ro)22.2(lo)18.6(gi)16.2(c)15.2(a)0(l)-464.2(s)14.3(ur)13.9(v)13(e)0(y)-459.5(o)0(f)-462.6(T)14.9(os)13(c)15.2(a)0(n)14.2(a)-464.1(vi)19.5(ru)14(s)-467.7(i)13.2(nf)17(ec)14.6(t)14(i)0(o)18.6(n)0(s)-458.1(i)0(n)-459.2(a)-470.7(hi)16.1(gh)19.4(-)14(r)0(i)16.6(s)0(k)]TJ 0 -1.2318 TD [(po)22.7(pu)14.4(l)13.2(a)0(t)18.6(i)0(o)18.6(n)-284.9(in)-278.4(It)19(al)17.8(y.)-275.9(Cl)18.3(i)13.2(n)-291.6(D)13.5(i)0(a)17.8(g)0(n)-275.2(L)0(a)19.4(b)-284.8(Im)16.3(mu)21.9(no)15.1(l)-281.4(2)0(0)15.9(0)0(3)22.6(;)-285.6(10)15.9(:4)20.3(83)22.6(4)15.9(84)22.6(.)]TJ 8.9663 0 0 8.9663 439.2566 411.5904 Tm [(Address)-339.4(correspondence)-340.1(to:)]TJ /F8 1 Tf 6.051 -1.2203 TD [(Koray)-338.1(Ergu)]TJ 4.3565 .0126 TD ()Tj .4489 -.0126 TD (nay)Tj -4.2806 -1.2203 TD [(Virology)-333.7(Unit)]TJ -9.2884 -1.2266 TD [(Department)-331.5(of)-336.3(Medical)-335.8(Microbiology)]TJ 6.9362 -1.2203 TD [(Faculty)-331.1(of)-336.3(Medicine)]TJ -.4742 -1.2203 TD [(Hacettepe)-337(University)]TJ 3.6863 -1.2266 TD (Morphology)Tj -2.5292 -1.2203 TD [(Building)-339(3)]TJ 6.7246 0 0 5.9768 522.3116 338.8535 Tm (rd)Tj 8.9663 0 0 8.9663 531.2692 334.8849 Tm (Floor)Tj -3.7179 -1.2203 TD [(06100)-332.7(Ankara)]TJ 2.9338 -1.2266 TD (Turkey)Tj -11.1599 -1.8273 TD (E-mail:)Tj /F5 1 Tf 3.2563 0 TD (ekoray@hacettepe.edu.tr)Tj /F3 1 Tf -43.9 50.539 TD [(SERODIAGNOSIS)-341.6(OF)-331.2(TOSCANA)-340.3(VIRUS)-333.8(EXPOSURE)-28299.6(787)]TJ ET endstream endobj 81 0 obj <>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]>>/Thumb 83 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 84 0 obj <> endobj 82 0 obj <>stream endstream endobj 85 0 obj [/Indexed/DeviceRGB 255 86 0 R] endobj 86 0 obj <>stream 8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0 b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup` E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn 6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O( l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~> endstream endobj 87 0 obj <>stream h,9@eF 5# #DLHB2ikReS^ʵy-$Hd%ޟ"z,O{ǿ?._\7No~8vk_ >\ax S%qvTQAU lC&5gՃ2ntmj`BWm˱1G|ܡ]ؘTL|xuvFu8fVs?ɭy]1`M3QMEF_No%-H( X%%d|PR"{p-XaqdL|dVpy3RZ@麡nk.`JW:n ;2 H"I`@!*!OXV\6BV@ԥ.%+"qGЈ{tAB=+wpܔE&j?' 6 endstream endobj 88 0 obj <> endobj 51 0 obj <> endobj 89 0 obj <> endobj 48 0 obj <> endobj 49 0 obj <> endobj 52 0 obj <> endobj 53 0 obj <> endobj 96 0 obj <> endobj 95 0 obj <>stream hT=o w~ǫ:ֈ%IZ58)RcC] >stream JLDFBH+AdvP4C4E51 l AdvP4C4E51#[j-e~~vVE=0c4:# jtqurf><$R?6s}{~{~~~ endstream endobj 94 0 obj <> endobj 90 0 obj <>stream hބU PGf̒Q,ښ]PˀZCf3xR (^τ-&qSTԠ1**Fj=~|=ͱ~}__%99H*jܘףfE&GFF)Lrbf?}0PK<\7&9Tu-|sF\݄4/]Iq8>N ԅLF]b%טeEg9&>h33u'Xtfhsy܌4.ârz1Ko^3-ddrs:}!de CޜaT?i$s%AzM%MYT+INR $'HåyRdáJVW]wutpSF@t$Ϩ9yZνGJ9ڼT7pB)P0CڧXgN{eF 0jܖmXGѴ6'!('-j&}ptZb>!NϚH_0aA `CYOZRԀ#H%8aR^0#AʾN?9KV H7PTRm{D A.V ۴c{_UܣpS'UxN^ [@P ^)\#0TL(l]#q,qZ:P d8´\<"^^i_ m` w-}4;@7MrOj,\`G3ɴR8S_Ώd^GAE%ٻ 0a'aaO܉ ?vOfhPj;؍[qNpg.M9BNu!xD`2SQJTThZE5IHqkkG?ٖTK+G|w_6nuЪ3S5a'G$Oey? N nUc 9u{AV"gqo%@&0hK ;|PS5:/ehcϓ38,Ddw74tE/W>ޯ,㚤Dֲud _)zfrtَ!>9kxWѢrb =bJ!ϑg.Md>9wy8V#ˆҘyl,c)>7G[[wpF+7M3CJ*ɲG@AMSQVPQQ{HeIIe 4?= "hD}lɤS` fBL ŵ_(t>x\nXIJrQ,/dJ.x1p6-:ZD.{幼_԰ғحko紽Os^KͮԦD92ܗB)I|3~o~ic7 W:Ao[ Ǽ~v?xŞPRXed'Q B>lb Cd&ާ-1p@md,Z nU BQxwTѥc+~.L2TB6і>RnCe)^jsR^lnWcBtK̿ovjOz~I9ᰪ'6Si ^z .nuܣ5xm55Դ2pLZN N`9ǓrH{SRV[$4[eNhT)֊"v 2p:7n7n&B[79qW /zbe:GJ8G {a6-Y,WPRVtŒBzؼ@;lEQDK/=4\y$[N 7 endstream endobj 93 0 obj <> endobj 92 0 obj <>stream hTP1n0 :lxIC۠N+)x᎔'@98Oq +@zt:'zrVȏ<;)AE4>21,1~ㄔN㫎ozBUG^ֈpڬ9jiDhvw@g374Nݍ-r#YszqP=)1UJ0Dj endstream endobj 98 0 obj <>stream JLDFBG+AdvP4C4E74 wR AdvP4C4E74 X|#p3Lp|~zx~M~c~kqqt-zx}wwx}}xww}x endstream endobj 91 0 obj <> endobj 99 0 obj <>stream 8;Z\7>F'ma$tV0lbPp+VmE>Q!??m*9&a+BjXV;<&KHse6?^q,3#PrUa/luB2Ge%0n %V!%.dp1Co\sps&b5`W"):"#,?e69@J>4:O+Ql#"_rIo0@XkNq,2d,G3+D`EUY^Bb J!IR[V$9H-iqMblrA++:5^-.NMSIgJW,$1+/`Oo-2aWM(r^AU[q;SB@Z!Zs[Wa6.A >f0fJroq(jF-%5CB-T;C$5Q@D.%Wl5>-OU_4c-l(f%KgiMNq,C9J&UuYO*8&>i[=' 7`Lcsh7Z=snT?b&]0]Xjj]]eXC.!K@aZ; endstream endobj 54 0 obj <>stream 8;Z]!>HYgs$q+5,J(aj*]U^!u$]SL,4*<$7C)#(DdS*EUG)>WhM>#0nV*3RKCs]L5 *Y!ORT7*]ARC7RTq-u_BToPoUW:^R\Lopk6p(>V;[(I_R,@+7rE,E(,F'cpPbPmY^;]Nu@A`Vku?IjKQ ?N3F7-=k]2_im\/R[`ea?Hk"c0C^TGJkM/',iu5PB^,BTpW#9IVqr?k6J2YAUJ\cu Gm3'>1q!()=dE,O+"QYY.BcDCQ,pufp(t7,o2>4$]IK[u+"\*IMA(Ikk]/c\V7\o* o>p\SYKPhDV1gQ,p endstream endobj 62 0 obj <>stream 8;Z\78WL_3%.n'+`rFrUmgKhj_(.JVAl0PA%SPiV.#`fRg'p^>PH6P=mg4[E/3s>j 2#F4mfPJfsZca*\,8R+/Ege0E@<:E%aos#oZ+4tV3Qrl1,! X'W]t/olqUR\-jd+ek`1EN<`-CPhe$ooLiBBtdWB]u68;\,;FEgd?Plb<&]NCiu[R (2?5&UN$b9E!Z,_JCNk\D$f9=,GY",d#aqc<:r,k@-lY;n!K[aYl;HfI)>_n:.lO6 ouH)p./u>qI7A1$N4$=A/h;D&N+]Be<(:i'i''IjpF7C?S("lDM]-@H\K?%djm-Q? ^:"YS/b]-FEJ4.NIU0C696L.JI0K=akY'd%B^,sS0+8*ZD[:_)SSP%)SS%Aii[XbN M%l?R3/)[5iTP'MW*oP?LY._)_)7`5Pi(rIFbZjr/q(*nSaQ%6GW4gV:?-I]L8Na8 4D.1,)IdG/p35>R><)uIo(&jCppIoh1OQ,[+kd3!IabjbL\-6lS__6W@sk7X7(?ltZTs_su7~> endstream endobj 67 0 obj <>stream 8;Z\7>AhA5#im]=j8N]M3_di9G1NWR(oaN7=06Z[R7q$s-6iJj@'R)Q0t7#fO6\R8 r&@_A5tom*f8j4Z`$.?eKjkG-GJO!ui7]2>EAd/3\-4LsDSH`8@f9MmY:EP_Z%o$# XMT?6^Y6W0(3+eq?aB/oYQ$Am%+jni`%P#;E1>f?)RK_T-3.B0)lo1Q+G"I&<_Y*1p;o,\%7lf(pdVYi3@WA;<"aQL7E O^@9sEEj7K!Dn@9-@E7L/ bFt`pQOW*ZII)N0C2naA\c]J%P8r`.]<=Z;oE4HpN;$SAYMm6f[o.:ANqY\HX8be< -ECX-?WDPXYk9^:^D;:c*eiQfL9$#WF)VNLf@-qO!P`1(=88tE7rd)'nR=(J3sLL`K]E]PJP%XGXLo3R0dDq:1f IkS,l endstream endobj 71 0 obj <>stream 8;Z\7D3fku#^%m$A,g=a4-TID!bt;t3A^2c0+5\@ogT_6B/^77K@]2Z^4FYZ^odUC #Wc0?mCbpH80Ts?Lb!!-+>PlBS^uS T^/Gb!;jq:c/\;lBC$D:+QKKb^mW?ZZ^h:JGPBf1dMHC[ e/)VsR3c4S_hFN"^/CklT6+nrKkj.[\^Af[0puVI@V);Mp q[nqP#VMjd(<^ZHItkF)r1lI#!4eF_h[9rLHTQ%ng`V(g.W+26@Z;*:E_C-k`usWi /k6om4tc)KaAsSI49iW'le4-T*`*)Yia:]GkD_8DnAQ9>qRN=R9,k0Z9MF)IIN-#h k\KO7N\?@uH[X0;s451NUJKmG^jVaTp8ob"[>\b4Ng';sBiB-0H\ZpZGEL%lou7Qb 6os>$-ksqXXG(sgVaMqtZ$7?R5f,6?r%)%:leH#?2KJ$2YLPi$Y?]BT8UbA,8\TU: qom'/"onjI!J(~> endstream endobj 75 0 obj <>stream 8;Z\7;6kfs%.l7QEWp3_$NerC7Mm4DT#l+Sq1-<55.YW:"[_93-oaTj`X%pNeqXg%9c%0& ^>@f6$*FO0@b,)ENH<SrlErl!f+,M'8*IErq/Z>`%'I)4 A&Ygh-MgUW_Wm-#_e3*8?RsaUUG%b#cCpalU$[oD:gBZ[JbhF-'n^RW>St&,I!n`P j$^qB^6V6,2(.[mNn-8aI?hWhgn(gCjJ*;>2OF9YK;BCTro.)0\,1JX_?_XY.+t5.W\[F``=:R5Ou?$G[q,k _kXln2HBLjVgS0hERn&50'iN^kT$Ki;PbPr1FI'0T8'4qf3%$1.L,(G/,:sc0AM/U CD8<\,P_CJdnD__"YQX;:\r5a`#2j53tKq](LLs1%5G1iGZtiIY81G1%$>)L!;3:: rC,]S(Gh2e1Q^"-BCI6To^AQV2TBSc^,YkKgl&>gq:fmB"sd-gqC3uFE0;7[V_H#t op%CHY\*K\bSuFf#ctXQ<(gSgQ!%`C1)S=h@CNu"rn$bFk+0-(fG67:Wo$?-8:#%G gkb8\rc\2J!6K-`-3~> endstream endobj 79 0 obj <>stream 8;Z\76+3RC#im\mEW<@aS^C7;6qt/J)?4/Pb%J3>M#iNdT\70aW&C3;hs^LQ&-!^9 LY.&na6'hs^Us@Uj*iSinnWO$Z#7Ol2tRga=BH>``&fZ!jdGh(8>!=rCb_0'EZpC^ UMIF1Y`ASb/t>!YQbGOW>*!;YgkWZu0W0`*qck@YoK6_*d"`!%Vf?k!@Wo5Ra^/6[ f"ll,LUPb"-epE.S*^uB8OrKUCd!s4Zde16S9E5q1E]84VRhcp@g^&*W)Vu#&^17W ^(=!Z6jUJk4QLL&X4qFheNM\jCW!Y/;sFc0I_Q/$X(S/?Son9pU-3,TE@HIeO`0?J ;=0L&XC]cYQ"(7s*41nQfNG63cD&"P08:*_eO!o+JO;TtJ;I=D:t>g$Z.K/=GJTou 9\5>@%":&LLD5tbjurk,C/Na2:K'mg[:C2pqM4cT$pWE2h&:>'b?B8Ud'Wr"N*Sm( :r?&hRH]hkB'/%'NF6t5b5Ne$f@Rh:&N^@NR$:i,I722tbC/-O&Jb7\aI0['(qL$s 8hj;j;F(H@b"VR0'#&(7?2VbA>-lXi]S-DO`S^DS<;\7VdCh%(a;KWQ`$okb/;X.a *TGEX]`kBMdEK9DQV_,da&pfFBACne/Hhc$4jQSd<^Lj^s5[=>NK><12;`9RrpXu0 XbMl/0E[TR:Fe;'I;Fd:DbSXp44WP>k"g!UH-.eO"Q(GlfIp\"n#uJZm'5t%ZLYAe 7'0iAH.BOYH_u7kId3n]"#GA1dPm9.l9AWHVu"OGg@F([dDOst.[boVo#3Dq+86^L >j4FuHf$@F4l[.,du_+CSbSrVKnY57KnY57Kn]OIIg,n5`L%8~> endstream endobj 83 0 obj <>stream 8;Z]LJH,ZM!5fq/_Wb=a!*'%"z!:ZEW!rsh\Y[m~> endstream endobj 100 0 obj <> endobj 101 0 obj <> endobj 44 0 obj <> endobj 103 0 obj <> endobj 102 0 obj <>/XObject<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/Font<>>>/Thumb 99 0 R/MediaBox[0 0 612 792]/Rotate 0>> endobj 116 0 obj <>/ProcSet[/PDF/Text]/Font<>>> endobj 112 0 obj <> endobj 113 0 obj <> endobj 47 0 obj <> endobj 114 0 obj <> endobj 50 0 obj <> endobj 120 0 obj <> endobj 122 0 obj <> endobj 46 0 obj <> endobj 104 0 obj <>stream HTˮ0fJ{K)+⊅۸&(IVAR:qsϜ ];z(Fd n2K >stream HTMo0WqkHh/M^ֻk 0+3=U\1~ޛaʤ\RʰeDUwM;E1c>E?wŎLx& ĩ0~ӯ53Y&f1mT`<&Û?6uDiRh7 (Z(:]zb}czL((&f6KhL1$@M2]}`Z4w^R"h Ďwz=.$ P,WfL䰹hй  ZC bFC[mMݓ!lC[iK|\=fCǒ-%0w.~|i1a_x`I2Of@昛+Q|ʐƓ~u[}l endstream endobj 106 0 obj <>stream HlT6WR.VZI% )5́k^"iPc_ vCWKĘ^pv2 b|bs~e+ ~gRhD kqºeO7UYQMU>-t5MۨAXx**!'@^Ւe vɽ9 #!.:pw~Np':щSH&5046!kѫ;inPߖSyk6+@~J<67f+ዡJRUD;Z{2Rv ,WZ<{8@E->$'騘_41:Oۧkelj˟@ļճ-𰪶i*.,18;ܰfzdzҲ1,'Ⴄxٲ㹼?cY3&9("..3Jϭg<oz7e@)Hbz]я̞9K B`4,nzcz`0cH7tSbdsT?:ޢ]s8Q/<q[Řqhm9Svs~.^v^F`\"-R[o‫W{t3 6a YfE3!̭UYߖ/ԐՉ/6Z2XN>@O~z0Nxz&_r~6Ztɲu,M]_#FCy0V endstream endobj 107 0 obj <>stream H\Tn0+|1."UWoE !YmhH c-*dzeu$aZ*(_T7WϔU:iCkVA*90Yr4E&t6ԫ f'd{MPIh40Bt뎾|}<0.UCpePJ34@@E@0S[YAtH@Tw߭~UW'޸Y-. q/L r Sf:ݩҝ\O"Ae|g_c_dW{hTd> endobj 61 0 obj <> endobj 60 0 obj <> endobj 126 0 obj <> endobj 127 0 obj <> endobj 125 0 obj <> endobj 108 0 obj <>stream HT0+z"jۉj%@bamn 8Rr` ةJWB=ｙ7¡6)302MX`vr+X ӌxψ"cġ~l@&g76D%+u1]TĴn,0om_~: >(aM #x ],zCì|1i(dDRT@p"7-Z% "iwi>,^aڠ.U6.hhq l{7ޛ _YƟ|SkUε5Ѫ'zr[7 fW@ݶcGb ]㆓Y8?>?rUU)Ӕ82 @k<{@E}@К<wa0Yʛ:`ݴ~- 4+\MaV0I1nբU-++z"MX)LQQ4}sU]<-*WZQU@en-iWlw!c9՜y eߖ '9 ﻡwո ΖqKQ +DC/I%Y"bjDDFwLApږi ~+˫b\i> <>@ƛRTK [W^fع1kGbM endstream endobj 109 0 obj <>stream HlTn0 +rTړ%۱- l zivPl`Kd~v2RJbˍIe!ES!,?޼b)DUv*ra_#lxD!\]za岨[ ra{7:oӵ([ б.+a21@W "KuފyaÄxA6dEFqa[SBvKlNED7{u,h;22f,:??FJfY&Eg{2]zb==oH)hR](E瑪(ř0}j㙤i1P]tQ94 ~p"R$λ2h$fgَpɷs>i j 0L@.` >҅D,MvEr[k^ʪLLsQK@g I} l6 9v;|O9h(>b_h2rcvE REeRıMS'q谪#1Q+lG8QyRѦNKU4K-x endstream endobj 115 0 obj <> endobj 110 0 obj <>stream H|Tˎ6+t3)&Vcm=f%c-vv9ُbuq,8PU sO똲-{f2 #Cq 2Oij:kyæjXup9l%\Rݛ8!q|)bmgbð;4BqBydeJ5)E_5f' RƔMqB+[vh^arp>Ҳ1"`D7ZF2%D;7OҲ~rC+WOS QOr)U@ R[<ί)ʃeO=i!ys8a 9E8NK\@EfowoɮP5qȐ_c:hY#H 5SBڔE0$-uǜ+qq)1w|qå[<mΉ5k֙f(3ƴ IE`D$cVۻUc|Zp%č(V4r[<#*]eߠg\DXnzU Y=E|C4UW<eQUV\35a5ΐ\wO|?Bʟmy SD?PTZ}qW]έrF͵{3 4u`nn(u Tri% lr݄=v-m 4N;n)zŲ>nK s͚ݐ*S>⏎$nʽcoz2 j { '7s9n?g@j0 endstream endobj 111 0 obj <>stream Hn0E -G!bw~5p؀f f6r~d]PÙ{ IARyJWJeI,T.:$G0:$03mol," # 5̉ٝ:۟}'fl3Jظ{>/nΉe{m(܅ێb.Mw3ɾW!JMTxPJ™-=D ׶Q÷־hL#lTÕٿ v] slyJ(yZ\Nomh8z<Pz]V0i5)1ֵs Zg{|^5:sa먷ngM]Uꡐ|,1T$ZW׋Yތ8f{`G7*c, /v ]hIIJ9'c,(xiu:LJ f$p8elC4s@69|ƿXc9_/?i(a/TO(g _2nDT'="rH_yXP%*I0 endstream endobj 123 0 obj <>stream hdV TSW~ֈ{OAjP_AAE@"P@+nժ AEXZR ⊵USEŪխ]jK'sܜ{2f曹O(B:%>*zZ°p1ё򙧤SHoc̾Koާ }'zG9ĒY(I*{P>VǎÍ4XRPh)'禛-yfKj8\-g73M&bzkZT*fb%hIdb|V$$LjfEm Y,S?c`t10>0Jڔ`"üٴڸ<0JFŸ3# cc~QUlTwz)tKHFm-ΠU+۔f HI#yT:WǪ_uTFW&#]̡hJwh*VYF4tDi;Ouusƥdpr5j\6տݺ- s=q|1k .qՇ6%AZY"ˮOA l+UG77_ׂa~&dOŃ7䏘6/S&$EeaZ0J 8G({A=@-ޑnr9dC }V~Q?83vFjEޛ:0 m~ i[mNcPf\+&lzF}C3_"W?n 6< cLfW_x>s2ٱ%2< | ZnM?om>0Ir~459}At}EW}\7﬙GfVVߊA$@g57glnRw{5ep!,Np˫4L*If1haR1rh: 7 !_:dTɌ9:j`˓uWȂjAS x _y)fki5&$g{*Mj~0 C?|ä>D#b8Uzr+ULA&8wu/ _Fy:\cE 'E!<\:g~Izz@oSKpG;^%tsݥVT_Tp~K{1`" w$$e/h! hF=ԴBvXܾxTOӢwKtup(jYvb((8׈RZ;rrA삜}G:'zgyȚїצ@n  Bp(Ȕ&P&HwA fx|1 .s8I`''d'q(\f1ՑnЫ4'+-ĠxБ6TlYBNʢ2.aO~[NϿX~}N5 IV~ԪEܔy۱m-|UM4 jxPC@[㮺 K9^W*m:hCw7Rgg D#8KALԀrPvuv7&Uea 7066j*Óߙu~R] P E.彺[]w 0X bUG b8@,-84* ^<q6jj5,hX<֜%ֿ,MOE'aߛ(Um -WZni?{*8՘[ͣA sI5 YUi]m k( 6nzLRrr{t6@sbWd#2GUı΁*HV ˃L!Pp 4`c("5 _cB~ .#tƙ%BwMby^E<N='=; bp%(}+$:ћ.n&apt݇$#L5u uVSQ^@uJJݘ췓sQKY!^o/;pJxif(s}3uB;pxA/]iw}:#YbLdRT~Bώ7~v_y vO8/HX, C Y:J]GYqpUЗ۠Fjq 0q endstream endobj 124 0 obj <>stream h޴Y XSWzk[ZwkUq(@}KHJaQnT֥ck̨80]:39|~y;n속Voq~{ePByM/ Uإ1ߍe/ 5u;`2^!d @/lG\)0 ٍlh. {\sc8{ ;*t^'ݣF=/,yF}Id̊1-c_2n¸f2~x 4aτT^N8I ({!oW^{&nоkN6I94n_>O|W61\ǻ/Ccߕ._fUǫn@vmkCf?CPbbx-8~J% EzxVβk3$bpzP&E` 8S,| v:t 48_M9y-0J€@G\A@!!5J<+{A2_2S7ZA;PMss-cuDKCCSSdRT,fZlU [C N 3f`<|` |fnt8Tp|# ΄sj@` c(Q,id̍O %1L&J$2q6$nrdo/^!KLRMcپSrHة؃s׮q'e?\Y8i!N ^[n_77lKi}t>" v2y{`&8o!{ObsGK'֭۹jQJ*ϥ; Xq>Yǽ?Vղ┼/w2ѳ|д2l廜Qгհ&ȏաǎ1|7$Ȯʰ(ʉ<tJ5 4`| !o1~8`mGHQom0X(z鶕799F蠃A9Rl=I>8) Ԛ@{ߌN[S+M;H[l0ݫP+:*QrPv! , B<>;)#"ҵ/Ϟ99 ϳ0<~Ι{b(v6ƝTl 1% i jӄ}k]Q "i}F+@޾b8.!w,F ?ZM }0;)RҌ-:V|5n ސoroqW@Um)DLJ[g!+:D=Hq PO_yߓfw ={bOAȮm(p^kH&9ƳSRR( 0>T #۟5X'D aΜ8<#S 1alQ 0|XC)'}?OEwvwsdwǓͧkq4t 3 TU56Ay >N>B_ׯT.V?lʿ )>2cK04}#d2dh  P=>MLdGVtF#a @ES$2u06:`Hsyez- Xt3- /+j<@>|gʻ]cc tq(33 $@%Ь;ˇ;z}=c)@e"4|[BUl,!Up^`n"m5 y.]՛Ce]BnwG(J܇$^g~%'p\Y`O}7;0JPf-:CM u&)\Y m=ě8kLMh.Ij> O{xv)&$E(uҨ_Y%++YsZRm{HեS:GGBΕPgRepJ K,TH.gQ<5lcB|pۄΊ' %PsPByzތ@C+{|~!Y eQdT.3)2&B\qz 8NGP`pKvis~$PZYZo2ttўpE n>Y>b>M;2='Cb =레MaR4in?#-M;d+g: mCˉ ?Yvsk5%m @.l*Ti*:2]$ PΒi@^zn(ǒ"s/y`-- 6!6Ƕ /!d=v N4frEx9Oك6$q<]Tgb 2Oq5#(:0Ÿ@|,GLȷ#>j[1v-d]SVBIc3RRDޡQetxʝ%- E1Q4xSx\^Y/-+ChD~j1 MWE뱈42|)0؁x425$@&wlOт0/8';8k5I{|Lc] ì R_2xsʛPʦ|R Lצ"j4;lElÍ[`@չ|GjZee4[P>aqە*/ҬN"RSS ϠK=-tkgjDD""VZ$Cb(yjjq:/q55uR@|\QHm&y?GܯmE*9-̓-(YkO'Q3ZGkN- NkK5jmB/Xe?;ߘw݈&oτ`d8R.O=$f͙'_~YAGG5L0?lA7`7<堮XHa[f&3R%sގ"rETsek_8ؚ̈́E[w#GlxOޙ.*Ī}wxdz=˛,1=$9pT0<>ןގGG~>R w:6DU X~V1GD("b8L!v2|I49؟lk/em:bu:DeA~̙PS՟H'iDYQ GFU\{pǪ"XZ%"jҠLWXk':;R\RIFk'?!o/SÔeVK,6{UzKc6'x+uTvOIz(Mej*W[hk [\KGP~*+0rMJTde[E L9k&͢us EM’+XM9#L&b1p9 Dʰ ׽WB,7TĥXlΆṝdi?la6 ,k̂-?S xږ)l#+}z endstream endobj 128 0 obj <>stream hWipSW`C[~a@$1`8ް lٖlcKd$ x :@7Hn Ss=Sse(*3US5%qssw9A4Q{kϘ4vlذ~]l潅(yOEy]pKKq[}o֯fύs3Ft Х(unɉdE2fF6G疬)ӈOQn*-%YW$ݴqJFMF"(*FHV)uȁDN"RGr]hHF$rsm^J8G Jh;"Yq6<~'Cz_(~qenܺWe&iu;wJwm,ߙ/P'ʼn^*Osf!p;hrI ON+OA31gZeum7*aU%ei<ng#S3CḫО Y~)Eo3u|rٺy*$/CB& E[_"BIv,s S+:AOUgx2Vvȵt^ <=sqFKWib~JfɢRi8>Gg! V]i ߡod(B02|#]l<=`jMe!I)]iYhZ!Kl>~ eZ99yR%T`` s&;ɾnhy,y|V:]9ĉ |sG%LAb ''*$?.1Ye2bc\ O@X,,j::a;zO?˖!Gq/}B#DȀ5A@ 'L-|u ɼddn8 KH>Χ5賾d0:Ao~Ԧhz'Y_UWlKar 6Z2v&D$۾ .cVKZ)H-ΒQ%ݳ)5\VRE \@.HTŽCr,Rh77jj媌e_YO{EA;lQ' zciץإ&hfM67fmğNHi -`埏 9ȾT|71?Lp,;kn@[t2\ymyxvft(r`I\)[nuߠb^"꾙v hW#$^׋>jnʞuj OK\Mʘ@ۇ4w1h16FfB]O/7]h64L45 ]qAp0Nr5=3 pfM3ԲȬHHfzym?M)ohdaO=>^x= ґk'W2\P *VKOư[me6\$h05x3^$ѺoovV}u0<2%;{o۞(h`qr83Moseۑv,>98bGz*Op@N)uY I?'qNLr$4S1xF$6*MF9P% B"k?: )eL{N NfR`!,""<Ř-`bTp-MifC,LX=ur*qZjDn}nB更vgRrkXҰvjn{ 1 U'a@lqEa9s8,[l vc^%-4ax 1r; -}kdQZ`zOw9 ,2D!wY'lhZh>'ת :!YbKf N@4whN0k vhz|GI^%,ZAC}^v ""!Y_uEK棂#*ΏN4AKU]nH b2Zk"*46 ^u,FVحqa DnZz L2FmYR>,C}CKߩ5aY'Q8FFy~^V}VӕF 6N36fuWT[geSLa =^-ϗ{d tWByv845 U K雨\m`ЦCΚN=2TO_iWg T "Vvu|kߚ(z 4y+dOFń=;Mv7j%q#ֱF{>lGIx¹x"wmya,Fgq]īwF[F3(Bc#-vŞ>s[_(~[rE홅r)dQ ӷ~gǣ@֟w#ȝ-į7!W ᒀZ'Ωoyjt޳7V>b֡yhdShdVIт%xn rD1ɜ4" 2ۤ׷ZUc24C;^.O(}};zsI>[OU+h7n0HJdKQA BZ8|q&[&eOǾrl( bM~yK:K|-n]B¢ y1_6 TeVW,Eh=^%Gq]҉ckgw5]vnzTcAf3S[$5FHCM%K`xO&ye 'mfz-oO endstream endobj 129 0 obj <>stream hޔY TSg ZMkk;o]ڪK֊ ( A$@܄YR{[mvT|?Ens8ùwyVVHHcG[5_Yp7?<.F XI a~XlkR+<5zY99kDrk%Ê̊ aYLHV(U:Ǻ.dbHlHG'MHLlC!0^s`RCaE>i7P! gN'nr^$ ѭ輅K,}+oַ[wyGe{|Adp έckI4j4I`-! 烑Q g gH w N%jE'Kş]@`&x@F 6"107D~Ivm{R m3yfs]3Btq^~6PX+$7d lerN1WvIdl)68 pNsx0 ċ?@|vzy D6~ 8Y`5x86.jtw\?%.*)"mݭemnޢ:MF罤ԉza|~j,mXgAvmV4Pu O~Jve i|$6j<J߾KdRIF&ZWgo??08 >MKp~=?_x.M$)jbm$? x u}3sFܑLPtwxVU݄a?GD&%aX'鐜0S `;:1,ڌLRs:~o01)% LV̡" 3uw.yQd,zO{(QeJY4=:g%ԅc&^,0t\oj›[fxPj U`ҟA8ݚNQ奯ͩd$1;X=Q8Pڐ]+ pƏ A2m ;>h>=`?b9M#)3:޽#bQz#=xA;"G a6\ 8 &HAZ;A Da =X=fo߉_!qkߞߒ3|&5}d$,ORP@B#8@RV^S^4yTG Ȝ0E^LFipzlLtb\o_TF{ >22xubYl2S24PxJ8:&9Hѥ-X6VPqfC2ЀWam|+ a#o@ օ0w+xieLk`yA~Z|R⫵᷇ҟ~aĶ,B|VOIPqnj7Ed{'mh0:؆`[ws|)q8| >5b/}O~ 4fDanՒDŪ8SUgszr/y͝}~g=,b졷tj i֚M\?ϥsЦ9d!|ib{޶x^g) h^k>_ _j4߽JqT+MT+;m13WXɛAbΡrlڔżtBNSDZ* ezWnPF/k.^Bmm&䩩lEeb<,WP:9)[BVU*P͖- Jr|u>+b z|ViW(bQ%ݪU*7]7=S~]K9rx`*~$R\ۀ1)9^rrQDoj8+g l\NLFl~ΔtD.1()+qhpbLl`OAm9k wl^xƇ}ĥ`z6eYًLwSN`I$<}}z߷_.PWJDcO!:j6)+"D'q*3[hÑf^MqHx82 0>!ňjCG&]}vs ~=õ*ȆDV- נP*F {rqrg8@0uB[ P 4b'@{Rw* (1)/>.;)5fLE􍹿Q&I@.,/f%oU]=sW_wV'CK J;nd|pA6%+Yg+>n>t6N((̰]wjA5!EޓѳyR"k YŹ)riYQ0 b–Wn}gϾf%+,5׶1dAa<3qUy5K| s -,7TFzoʋZrᭃm<CW] B#g8tsP Ir71&Ar'ϪחYx`W[@ܔ# ΒU@o+L CPAkch-J-;ڲsJԮoZJK)VUKʩe{{:\Op2> auO8Z]-Xxd\nPhF&U:fl9'?\"{q[EUU!Z|\Sz-~D5Uj-n )RVmQdvm?2V\^2%ejlŏ{fksfDPk|.mRGµp;(['{uS‘hcFَuY7RËthv `KQ-K:~ $U߄Xd)c")&rg47 ;@45;k"D;xo w)٭ǜ2oiSP8O$mhohD$oƒi`_5S endstream endobj 130 0 obj <>stream ht{Tgpfvj2SE]zZHqr'R Bf! WAUQTԳkEZ۳_؏y{<缿Hy.>us>_bTs2BZJܙy@`t|C= ыȎ~^՗T)҃K[ RǼtY \eƤ(7à-v.AΠ%cfKKysGي.abȘ`Ca*Ƣ)9!wZSfqڹE 愲D4j<7T6D]bo+;%0""Z:<[Uj6O-B./z$hVt,+"a67fib HQRaLHiJfI"xB}iLQ7:݁UuErͳ ZhΓͶytbI7J%Rޡ5J wO~wO78 H& W ,r:Q dKf1LPC trTvOaif FA*<_5;՞C7 pjhn._o^&?;-jx:{FKr TL#vf#p\ëSƟ/Xswgwu/51h>2IEF|2Ա|+z~4DpfD:THW^:N[OPT W ##y#_> 񮢽ݳձ+۲;:S>stream hTV TT=wRsHGq7I@@TFb-|Ҙ?I4( Fj%K-DEzHxۗ;c{uY>Wh\J«1 s|" D8edA%rag08sԐJU^e]Sd^"rC`Hpsl q!,kŐ\oYgʹXm|K$!b*3 y%b+YUL!;`6YfJu!>;ך_bx` T7 #/;+l˶M+FE?y Ìtah a.4 cHS1 j&Yä@ Fð(zD22&ìrWuzzzQ uEv2{x+tsC9\9I7M^R5E1vw/_rnX G{ ؉$c=YGG>X¶9~1:+m!ǧ=1ZՁWtL•^'1!$䀗Hc׋`#v 0Rxdy3JąoFrAAaӍ]j=460,yLqv(s 0qėb:Oa5 lpyЩ8)[G5ΞwMQUObKh/e ěGD&Lk%΋6.DRwz:F[|9_X~6W\zlKc=Y C]fF7 ͧI[n'%,jhFR;, ̍7KFJ#\7: ǗÑ` Ċ|Ҵjz_!& Ʌi_g_ׂv`#E f,>3_bP/5ҧ ! $̤S;[xp]&hAõXS>jus@oAw|;uPO 218GFC]q!/IΈn^Mne4gt+5r-(ɑO4?ֲ[aVT@åSN,?eQ蕧-R#!~YB2.ʟSo9unYbA#y aX~0Kp_!q?Aw"gE䇯s&&"<BmX7A pIkrC՛ t#J3Ϩ֞=r@8xϩlۨY-a3}v &v##5>sXlXԏ!E1'(IȬ9WRhcN> 3\t@Bּgi=T_ TvU:\y(tsBIzg,2(Igq%ߣ'9Q>eC寝i;+ ]S)K8E צ3Ǐʳj*vnrEŻHp=NE:p66?$.ŖkAUyeZz}=Ӂ$%nY`hPi ȥOIr{0è] rh#){}to]$l%I>_t)OchsK(XE؏ 3/ (MG~C!UOHQ]Dy:.a SQ,'>n|ֻ=$ٶ+Oɏ{ʱ<ؾC2$jG翏 Bе<.&f-h;X VrE湫w#H[BB,m]\e7_mlǛu- SI*|d 0ǫ\ԣV2`_^S}ݵ.OJDfx+::[|KVqE+k'',ur8ST]R-BQq~ɕ"}L9u<O Ya{ ,kXx)Mo#͛7 yE;Ka\I垒 尼KLtLډ,mʄHh;ŝ_}Q~W endstream endobj 117 0 obj <> endobj 135 0 obj <>stream hތU}PWewfvE)o眑wYX]acQ`%*&xhe)> ~{1wgNEEbB(h \gqׯݿQQ/JRH2+4ޑ7k|䑍.G[dKG[܎ઁ8j @0*04,TkC}/ƒL.3+}fULUsC Zo?8L3,H <7Qg2;#0pf^I <ʠ٭piDRI]0|R}=4R#_ióޚsj㑾 b>M ;KVجunVCtEvag04k#~xũ?$ݔV_@TdD~|qutcТ)e]_&@8XeK$,rbRB |+-uX5-KZ6qۮWuJ5vRT:B\X5  D_ kXy!LO}{4%r49O[3vvٲ|y1R%5QiρJPtw @_ E? ,'ӑ3xfp 0HKC֠IOFJy 8> ʲ$lճijΜ²)3<`kZy\lNzr()0 'LI@N ?9Tg ÑMh!']z `B­iFPtZ5]<7&g'H>{ @ڪ Yӂs%F\֫ wG bo~]杤S@z 5P  /0Đ,Sd֑{=ZnK! `>q5Sa-GV^8x`{Q/CfVLPv|"u*ľo*iͤĬ~t­$+og0aFR>([WVV GKzt0 Ggct8D,ſ\O2 7]ff%{la@c!f ^znc3 endstream endobj 119 0 obj <> endobj 118 0 obj <> endobj 136 0 obj <>stream h|Uip^?YtQ(v]4SO2pm06-/ɶN.\U%˒ll>$ 'd7 eZL4+dkͤNg><|f@}4H ܳo4)2#>xo?G[eP@N)토= AyP>d@E')(Q Fo75o޲ 23 "֛,mgt x=}yFXV#3.8X!*N]d_&mc~!^,abYC2ȗ>vH:ZC=$ro0զHp4w_/ }~O&fdkk4UזV !"i3EdM^U+v(Z%䋹pC=񐒼S#fE.y]^G5V%P)mDot>9,E4Rvmt=Eae*:LL c]AÙ|X89}wKFPT0fEiiz[0;l[,q.O-oĪ%E\!^B>u. -^$6GF)/ܪ%ց%!h"Ru^3 B,@}K24-U5p ކ hI}=^Y+F9J^BiE43j 7?TvD$1s;n.Mꆀ`Y0>Gal5p-8f&>VJMkRH-ɣkkUosaFH2{gRkgN bnϾ+/5i S풐[$=^MStj:V<6/gD?ZD"_OM̠JhG`ry";1O::"pTWK٪_GnMNQjڢ-$E]y}jQ| ߙǖfUK-O2:?(ijL}d73KP _ mqE)c{1FLA0{QݤxU4%=҂o&z]s]s,߹ A?#*C/_XDՃMYq xY(pG:'7R 6ZѲ{t\:pc| _cKl24?5p w?_^F%zטoq~XΏZߨU5b.#YBdʯ }}DƠL79G(v:=mQL[vx:}ӮA~|>Zz  Rޔouz$v/Lf0/)s̐PT'Յфg+ :Rȥ+؅D"tv-oK^ ⨻i|I8VxوBXN״Cͺ]|rF.ƦBkꁢj lj E* ІVs ,]$l/y'||,]a(3I-,e_V_YS9 BXOcVb-yω,?,POB@7I`^gyKU 3v*AYv_vJ_o&18]Hȏo@tz''jMaAp%0ARY=I> endobj 137 0 obj <>stream hbd`ad`ddqq pvL) {X_^,+FnfFF&|~qh+Cw(FYv<|;vY3#34!~rvKxwbE=z@` `bm -4H\ bb endstream endobj 133 0 obj <> endobj 132 0 obj <>stream hTP=0 +<Ҳ!UOO(DM{R@oI>tg]S OtKwk; _:݄SdcqPB> endobj 138 0 obj <> endobj xref 0 139 0000000000 65535 f 0000005855 00000 n 0000000015 00000 n 0000000105 00000 n 0000001751 00000 n 0000005583 00000 n 0000003941 00000 n 0000005309 00000 n 0000006127 00000 n 0000003120 00000 n 0000000378 00000 n 0000004214 00000 n 0000003393 00000 n 0000001203 00000 n 0000001478 00000 n 0000004487 00000 n 0000002845 00000 n 0000005036 00000 n 0000002298 00000 n 0000000653 00000 n 0000002025 00000 n 0000006399 00000 n 0000000928 00000 n 0000002572 00000 n 0000003667 00000 n 0000004761 00000 n 0000006673 00000 n 0000010104 00000 n 0000010181 00000 n 0000010292 00000 n 0000010369 00000 n 0000010480 00000 n 0000010557 00000 n 0000010668 00000 n 0000010745 00000 n 0000010857 00000 n 0000010934 00000 n 0000011044 00000 n 0000011121 00000 n 0000011231 00000 n 0000011308 00000 n 0000011419 00000 n 0000011496 00000 n 0000011606 00000 n 0000101581 00000 n 0000012106 00000 n 0000105708 00000 n 0000103286 00000 n 0000090709 00000 n 0000091076 00000 n 0000104091 00000 n 0000090249 00000 n 0000091242 00000 n 0000091412 00000 n 0000096198 00000 n 0000011957 00000 n 0000028924 00000 n 0000029435 00000 n 0000029633 00000 n 0000030130 00000 n 0000110024 00000 n 0000109431 00000 n 0000096912 00000 n 0000029983 00000 n 0000043322 00000 n 0000043821 00000 n 0000109082 00000 n 0000097682 00000 n 0000043675 00000 n 0000049639 00000 n 0000050139 00000 n 0000098654 00000 n 0000049993 00000 n 0000062137 00000 n 0000062575 00000 n 0000099469 00000 n 0000062460 00000 n 0000077890 00000 n 0000078306 00000 n 0000100354 00000 n 0000078202 00000 n 0000088580 00000 n 0000088863 00000 n 0000101337 00000 n 0000088828 00000 n 0000088910 00000 n 0000088958 00000 n 0000089470 00000 n 0000090038 00000 n 0000090432 00000 n 0000092576 00000 n 0000095441 00000 n 0000094859 00000 n 0000094644 00000 n 0000092509 00000 n 0000091788 00000 n 0000091566 00000 n 0000092080 00000 n 0000095141 00000 n 0000095499 00000 n 0000101517 00000 n 0000101555 00000 n 0000101767 00000 n 0000101684 00000 n 0000105810 00000 n 0000106500 00000 n 0000107331 00000 n 0000108256 00000 n 0000111553 00000 n 0000112335 00000 n 0000113321 00000 n 0000114186 00000 n 0000102364 00000 n 0000102769 00000 n 0000103782 00000 n 0000113153 00000 n 0000102195 00000 n 0000137833 00000 n 0000140500 00000 n 0000140182 00000 n 0000104838 00000 n 0000142880 00000 n 0000105181 00000 n 0000114857 00000 n 0000117485 00000 n 0000111255 00000 n 0000110554 00000 n 0000110852 00000 n 0000123779 00000 n 0000127533 00000 n 0000133108 00000 n 0000143926 00000 n 0000143642 00000 n 0000143419 00000 n 0000135307 00000 n 0000138179 00000 n 0000140672 00000 n 0000143131 00000 n 0000143991 00000 n trailer <<6aa1213797c8d02841449fbbb62b02e7>]/Info 138 0 R/Size 139>> startxref 144604 %%EOF